Trial Outcomes & Findings for A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis (NCT NCT02969525)

Last Updated: 2023-03-20

Results Overview

The ACR50 response rate was based on 50% improvement relative to Baseline in the following measures: * Tender Joint Count (TJC) based on 78 joints * Swollen Joint Count (SJC) based on 76 joints * 3 of the 5 remaining core set measures: * Disease activity as assessed by Patient's Global Assessment of Disease Activity (PGADA) * Disease activity as assessed by Physician's Global Assessment of Disease Activity (PhGADA) * Pain as assessed by Patient's Assessment of Arthritis Pain (PtAAP) * Physical function as assessed by Health Assessment Questionnaire - Disability Index (HAQ-DI) * Acute phase response as assessed by high sensitivity C-reactive protein (hs CRP).

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

206 participants

Primary outcome timeframe

Week 12

Results posted on

2023-03-20

Participant Flow

The study started to enroll patients in October 2016 and concluded in July 2018.

The study included a 28-Day Screening Period, followed by a Double-blind Period from Day 1 to Week 12, prior to treatment re-randomization, a Dose-blind Period, from Week 12 after the treatment re-randomization and up to Week 48 and a Safety Follow-Up (SFU) Period, post week 48. The Participant Flow refers to the Randomized Set and Dose-Blind Set.

Participant milestones

Participant milestones
Measure	Placebo Participants received Placebo during the 12 Weeks Double-Blind Period.	BKZ 16 mg Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.	BKZ 160 mg Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.	BKZ 160 mg LD Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.	BKZ 320 mg Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.	Placebo - BKZ 160 mg After the 12 Weeks Double-Blind Period participants randomized to Placebo were re-randomized to receive Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) for 36 weeks in the Dose-Blind Period.	Placebo - BZK 320 mg After the 12 Weeks Double-Blind Period participants randomized to Placebo were re-randomized to receive Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) for 36 weeks in the Dose-Blind Period.	BKZ 16 mg - BKZ 160 mg After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 16 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period.	BZK 16 mg - BZK 320 mg After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 16 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 320 mg Q4W for 36 weeks in the Dose-Blind Period.	BZK 160 mg LD - BZK 160 mg After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period.	BZK 160 mg - BKZ Dose 160 mg After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period.	BKZ 320 mg - BKZ 320 mg After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 320 mg Q4W for 36 weeks in the Dose-Blind Period.
Double-Blind Period STARTED	42	41	41	41	41	0	0	0	0	0	0	0
Double-Blind Period Completed Double-Blind Period	42	41	40	39	41	0	0	0	0	0	0	0
Double-Blind Period Completed Wk12 and Started Dose-Blind	40	41	40	37	41	0	0	0	0	0	0	0
Double-Blind Period COMPLETED	40	41	40	37	41	0	0	0	0	0	0	0
Double-Blind Period NOT COMPLETED	2	0	1	4	0	0	0	0	0	0	0	0
Dose-Blind Period STARTED	0	0	0	0	0	20	20	22	19	37	40	41
Dose-Blind Period COMPLETED	0	0	0	0	0	20	18	22	18	34	38	39
Dose-Blind Period NOT COMPLETED	0	0	0	0	0	0	2	0	1	3	2	2

Reasons for withdrawal

Reasons for withdrawal
Measure	Placebo Participants received Placebo during the 12 Weeks Double-Blind Period.	BKZ 160 mg Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.	BKZ 160 mg LD Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.	Placebo - BZK 320 mg After the 12 Weeks Double-Blind Period participants randomized to Placebo were re-randomized to receive Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) for 36 weeks in the Dose-Blind Period.	BZK 16 mg - BZK 320 mg After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 16 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 320 mg Q4W for 36 weeks in the Dose-Blind Period.	BZK 160 mg LD - BZK 160 mg After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period.	BZK 160 mg - BKZ Dose 160 mg After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 160 mg Q4W for 36 weeks in the Dose-Blind Period.	BKZ 320 mg - BKZ 320 mg After the 12 Weeks Double-Blind Period participants randomized to Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) were re-randomized to receive BKZ 320 mg Q4W for 36 weeks in the Dose-Blind Period.
Double-Blind Period Adverse Event	0	1	1	0	0	0	0	0
Double-Blind Period LOW EGFR	0	0	1	0	0	0	0	0
Double-Blind Period Study medication discontinued prior Wk12	2	0	2	0	0	0	0	0
Dose-Blind Period Adverse Event	0	0	0	0	0	1	1	1
Dose-Blind Period Withdrawal by Subject	0	0	0	2	1	2	0	0
Dose-Blind Period Non-cooperating patient	0	0	0	0	0	0	0	1
Dose-Blind Period Withdrew before Safety Follow-up visit	0	0	0	0	0	0	1	0

Baseline Characteristics

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period.	BKZ 16 mg n=41 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.	BKZ 160 mg n=41 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.	BKZ 160 mg LD n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period.	BKZ 320 mg n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period.	Total Title n=206 Participants
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Age, Categorical Between 18 and 65 years	38 Participants n=5 Participants	35 Participants n=7 Participants	40 Participants n=5 Participants	36 Participants n=4 Participants	36 Participants n=21 Participants	185 Participants n=8 Participants
Age, Categorical >=65 years	4 Participants n=5 Participants	6 Participants n=7 Participants	1 Participants n=5 Participants	5 Participants n=4 Participants	5 Participants n=21 Participants	21 Participants n=8 Participants
Age, Continuous	49.02 years STANDARD_DEVIATION 12.07 • n=5 Participants	49.98 years STANDARD_DEVIATION 13.56 • n=7 Participants	48.00 years STANDARD_DEVIATION 11.65 • n=5 Participants	49.05 years STANDARD_DEVIATION 12.99 • n=4 Participants	50.39 years STANDARD_DEVIATION 12.08 • n=21 Participants	49.29 years STANDARD_DEVIATION 12.39 • n=8 Participants
Sex: Female, Male Female	18 Participants n=5 Participants	17 Participants n=7 Participants	21 Participants n=5 Participants	27 Participants n=4 Participants	18 Participants n=21 Participants	101 Participants n=8 Participants
Sex: Female, Male Male	24 Participants n=5 Participants	24 Participants n=7 Participants	20 Participants n=5 Participants	14 Participants n=4 Participants	23 Participants n=21 Participants	105 Participants n=8 Participants
Race/Ethnicity, Customized Asian	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants
Race/Ethnicity, Customized Black	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	5 Participants n=8 Participants
Race/Ethnicity, Customized White	40 Participants n=5 Participants	40 Participants n=7 Participants	39 Participants n=5 Participants	40 Participants n=4 Participants	41 Participants n=21 Participants	200 Participants n=8 Participants

PRIMARY outcome

Timeframe: Week 12

Population: The Full Analysis Set (FAS) consisted of all randomized study participants who received at least 1 dose of investigational medicinal product (IMP) and had a valid measurement of the primary efficacy variable at Baseline.

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
ACR50 (American College of Rheumatology 50% Improvement) Response at Week 12	7.1 percentage of subjects	26.8 percentage of subjects	41.5 percentage of subjects	46.3 percentage of subjects	24.4 percentage of subjects

SECONDARY outcome

Timeframe: Week 12

Population: The FAS consisted of all randomized study participants who received at least 1 dose of IMP and had a valid measurement of the primary efficacy variable at Baseline.

The ACR20 response rate was based on 20% improvement relative to Baseline in the following measures: * TJC based on 78 joints * SJC based on 76 joints * 3 of the 5 remaining core set measures: * Disease activity as assessed by PGADA * Disease activity as assessed by PhGADA * Pain as assessed by PtAAP * Physical function as assessed by HAQ-DI * Acute phase response as assessed by hs CRP Note: Nonresponder imputation was used to account for missing data in the primary analysis, the study participants with a missing ACR score at Week 12 or who discontinued IMP prior to the Week 12 Visit were considered nonresponders for the primary analysis.

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
ACR20 (American College of Rheumatology 20% Improvement) Response at Week 12	19.0 percentage of subjects	53.7 percentage of subjects	73.2 percentage of subjects	61.0 percentage of subjects	51.2 percentage of subjects

SECONDARY outcome

Timeframe: Week 12

Population: The FAS consisted of all randomized study participants who received at least 1 dose of IMP and had a valid measurement of the primary efficacy variable at Baseline.

The ACR70 response rate was based on 70% improvement relative to Baseline in the following measures: * TJC based on 78 joints * SJC based on 76 joints * 3 of the 5 remaining core set measures: * Disease activity as assessed by PGADA * Disease activity as assessed by PhGADA * Pain as assessed by PtAAP * Physical function as assessed by HAQ-DI * Acute phase response as assessed by hs CRP Note: Nonresponder imputation was used to account for missing data in the primary analysis, the study participants with a missing ACR score at Week 12 or who discontinued IMP prior to the Week 12 Visit were considered nonresponders for the primary analysis.

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
ACR70 (American College of Rheumatology 70% Improvement) Response at Week 12	4.8 percentage of subjects	12.2 percentage of subjects	19.5 percentage of subjects	31.7 percentage of subjects	14.6 percentage of subjects

SECONDARY outcome

Timeframe: Week 12

Population: Subset of of study participants in the FAS with at least (≥) 3 percent (%) psoriasis (PSO) Body Surface Area (BSA) at Baseline (NRI).

The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=20 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=14 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=16 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=17 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=11 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
PASI90 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1	10.0 percentage of subjects	35.7 percentage of subjects	62.5 percentage of subjects	52.9 percentage of subjects	45.5 percentage of subjects

SECONDARY outcome

Timeframe: Week 12

Population: Subset of of study participants in the FAS with at least (≥) 3 percent (%) psoriasis (PSO) Body Surface Area (BSA) at Baseline (NRI).

The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=20 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=14 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=16 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=17 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=11 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
PASI75 (Psoriasis Area Severity Index) Response at Week 12 in the Subgroup of Subjects With Psoriasis Involving at Least 3 % Body Surface Area (BSA) at Baseline/Day 1	10.0 percentage of subjects	57.1 percentage of subjects	68.8 percentage of subjects	70.6 percentage of subjects	72.7 percentage of subjects

SECONDARY outcome

Timeframe: From Screening Period until the Safety Follow-Up Visit (up to Week 72)

Population: The Safety Set (SS) consisted of all randomized study participants who received at least 1 dose of IMP. The 160mg LD group and 160mg groups are combined into one column to see the effect of the 160mg dose overall.

An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=126 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=80 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Percentage of Participants With at Least One Adverse Event (AE) During the Study	57.1 percentage of participants	33.33 percentage of participants	74.6 percentage of participants	72.5 percentage of participants	—

SECONDARY outcome

Timeframe: From Screening Period until the Safety Follow-Up Visit (up to Week 72)

A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalization or prolongation of existing hospitalization * Is a congenital anomaly or birth defect * Is an infection that requires treatment parenteral antibiotics * Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=126 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=80 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Percentage of Participants With at Least One Serious Adverse Event (SAE) During the Study	2.4 percentage of participants	0 percentage of participants	6.3 percentage of participants	0 percentage of participants	—

SECONDARY outcome

Timeframe: From Screening Period until the Safety Follow-Up Visit (up to Week 72)

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=126 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=80 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Percentage of Participants Who Withdrew Due to an Adverse Event (AE) During the Study	4.8 percentage of participants	0 percentage of participants	4.8 percentage of participants	2.5 percentage of participants	—

SECONDARY outcome

Timeframe: Baseline, 30 min and 1 hour post dose, Week 1, Week 2, pre- and post dose for the following Weeks: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 and 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Diastolic and systolic blood pressure were measured in millimeters of mercury (mmHg).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 12 post dose	-0.3 mmHg Standard Deviation 9.6	-2.0 mmHg Standard Deviation 10.0	0.3 mmHg Standard Deviation 8.3	-1.8 mmHg Standard Deviation 7.9	-2.6 mmHg Standard Deviation 8.0
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 16 post dose	-3.0 mmHg Standard Deviation 9.1	-1.9 mmHg Standard Deviation 8.3	-1.7 mmHg Standard Deviation 9.2	-1.1 mmHg Standard Deviation 7.9	-2.4 mmHg Standard Deviation 8.7
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 24 pre-dose	-0.4 mmHg Standard Deviation 7.6	-1.6 mmHg Standard Deviation 7.2	-0.7 mmHg Standard Deviation 9.3	1.0 mmHg Standard Deviation 6.9	-1.0 mmHg Standard Deviation 6.6
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 24 post dose	-0.6 mmHg Standard Deviation 7.5	-1.7 mmHg Standard Deviation 7.9	-0.3 mmHg Standard Deviation 8.2	-0.3 mmHg Standard Deviation 7.6	-1.4 mmHg Standard Deviation 7.9
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 28 pre-dose	1.4 mmHg Standard Deviation 7.9	-0.6 mmHg Standard Deviation 9.7	0.9 mmHg Standard Deviation 9.5	-0.6 mmHg Standard Deviation 6.9	-0.5 mmHg Standard Deviation 7.5
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 32 pre-dose	0.2 mmHg Standard Deviation 8.5	-1.7 mmHg Standard Deviation 8.6	1.6 mmHg Standard Deviation 9.2	-0.3 mmHg Standard Deviation 9.3	-1.2 mmHg Standard Deviation 8.6
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 36 post dose	1.6 mmHg Standard Deviation 7.7	-1.6 mmHg Standard Deviation 9.2	1.3 mmHg Standard Deviation 9.3	-1.7 mmHg Standard Deviation 6.8	-0.1 mmHg Standard Deviation 7.1
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 40 post dose	0.9 mmHg Standard Deviation 7.7	-1.8 mmHg Standard Deviation 9.1	0.2 mmHg Standard Deviation 8.3	-0.8 mmHg Standard Deviation 6.6	-0.1 mmHg Standard Deviation 7.3
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 44 pre-dose	1.4 mmHg Standard Deviation 9.3	-2.1 mmHg Standard Deviation 7.7	1.3 mmHg Standard Deviation 9.2	-0.4 mmHg Standard Deviation 6.7	-2.4 mmHg Standard Deviation 10.9
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure 1 hour post dose	-0.6 mmHg Standard Deviation 9.4	-2.0 mmHg Standard Deviation 10.5	0.2 mmHg Standard Deviation 8.7	1.0 mmHg Standard Deviation 8.4	-1.8 mmHg Standard Deviation 7.1
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 8 post dose	-3.2 mmHg Standard Deviation 12.6	-1.9 mmHg Standard Deviation 11.6	-0.3 mmHg Standard Deviation 11.1	-2.8 mmHg Standard Deviation 10.2	-1.9 mmHg Standard Deviation 12.0
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 12 pre-dose	-3.3 mmHg Standard Deviation 12.4	1.6 mmHg Standard Deviation 13.7	-3.1 mmHg Standard Deviation 11.7	-4.4 mmHg Standard Deviation 10.8	-2.6 mmHg Standard Deviation 9.7
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 12 post dose	-3.9 mmHg Standard Deviation 14.1	2.1 mmHg Standard Deviation 11.1	-1.9 mmHg Standard Deviation 12.0	-3.6 mmHg Standard Deviation 10.1	-2.4 mmHg Standard Deviation 10.1
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 16 pre-dose	-3.6 mmHg Standard Deviation 15.1	-2.3 mmHg Standard Deviation 12.3	-4.3 mmHg Standard Deviation 11.3	-4.3 mmHg Standard Deviation 12.5	-2.3 mmHg Standard Deviation 11.4
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 16 post dose	-3.7 mmHg Standard Deviation 17.1	-2.6 mmHg Standard Deviation 11.7	-3.4 mmHg Standard Deviation 12.7	-2.7 mmHg Standard Deviation 11.0	-5.7 mmHg Standard Deviation 8.5
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 24 post dose	-2.6 mmHg Standard Deviation 10.9	-2.8 mmHg Standard Deviation 10.5	-2.2 mmHg Standard Deviation 11.7	-3.0 mmHg Standard Deviation 9.7	-1.1 mmHg Standard Deviation 10.5
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure 30 min post dose	1.3 mmHg Standard Deviation 8.9	-1.2 mmHg Standard Deviation 4.9	-1.2 mmHg Standard Deviation 5.4	0.6 mmHg Standard Deviation 6.1	-0.6 mmHg Standard Deviation 5.3
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure 1 h post dose	1.1 mmHg Standard Deviation 8.8	-2.0 mmHg Standard Deviation 6.3	-0.7 mmHg Standard Deviation 8.1	1.2 mmHg Standard Deviation 6.7	-1.0 mmHg Standard Deviation 5.5
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 1	0.1 mmHg Standard Deviation 9.6	-0.3 mmHg Standard Deviation 6.5	0.6 mmHg Standard Deviation 11.4	-0.9 mmHg Standard Deviation 6.6	-0.4 mmHg Standard Deviation 6.5
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 2	0.7 mmHg Standard Deviation 10.4	-0.7 mmHg Standard Deviation 6.5	-1.0 mmHg Standard Deviation 8.9	-2.7 mmHg Standard Deviation 8.3	-0.1 mmHg Standard Deviation 9.0
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 4 pre-dose	0.0 mmHg Standard Deviation 8.2	-1.7 mmHg Standard Deviation 8.4	-1.4 mmHg Standard Deviation 10.7	-0.8 mmHg Standard Deviation 7.8	-1.3 mmHg Standard Deviation 7.4
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 4 post dose	-2.0 mmHg Standard Deviation 8.7	-1.0 mmHg Standard Deviation 7.3	-1.2 mmHg Standard Deviation 8.9	-0.9 mmHg Standard Deviation 8.3	-1.6 mmHg Standard Deviation 7.6
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 8 pre-dose	1.0 mmHg Standard Deviation 8.2	-1.3 mmHg Standard Deviation 8.7	0.3 mmHg Standard Deviation 8.7	-0.5 mmHg Standard Deviation 7.0	0.2 mmHg Standard Deviation 6.9
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 8 post dose	-0.9 mmHg Standard Deviation 9.1	-1.1 mmHg Standard Deviation 8.4	0.6 mmHg Standard Deviation 8.7	-0.7 mmHg Standard Deviation 7.3	-2.2 mmHg Standard Deviation 7.4
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 12 pre-dose	0.2 mmHg Standard Deviation 9.1	-1.1 mmHg Standard Deviation 10.4	0.2 mmHg Standard Deviation 8.5	-1.5 mmHg Standard Deviation 7.9	-0.6 mmHg Standard Deviation 8.2
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 16 pre-dose	-2.7 mmHg Standard Deviation 9.6	-3.5 mmHg Standard Deviation 8.9	-0.8 mmHg Standard Deviation 8.6	-1.2 mmHg Standard Deviation 8.7	-0.4 mmHg Standard Deviation 7.9
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 20 pre-dose	0.5 mmHg Standard Deviation 10.3	-1.8 mmHg Standard Deviation 9.0	-0.6 mmHg Standard Deviation 8.3	-1.4 mmHg Standard Deviation 8.3	-1.8 mmHg Standard Deviation 7.3
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 20 post dose	0.1 mmHg Standard Deviation 9.5	-3.1 mmHg Standard Deviation 8.3	-0.4 mmHg Standard Deviation 9.2	-3.0 mmHg Standard Deviation 9.3	-2.6 mmHg Standard Deviation 7.1
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 28 post dose	1.2 mmHg Standard Deviation 8.7	-2.0 mmHg Standard Deviation 9.4	1.2 mmHg Standard Deviation 9.0	-0.2 mmHg Standard Deviation 7.1	-1.8 mmHg Standard Deviation 7.1
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 32 post dose	0.7 mmHg Standard Deviation 10.0	-3.0 mmHg Standard Deviation 8.6	0.1 mmHg Standard Deviation 9.6	-0.6 mmHg Standard Deviation 8.5	-2.1 mmHg Standard Deviation 8.5
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 36 pre-dose	0.0 mmHg Standard Deviation 8.6	-0.6 mmHg Standard Deviation 9.2	1.4 mmHg Standard Deviation 8.9	-0.9 mmHg Standard Deviation 7.2	0.8 mmHg Standard Deviation 7.5
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 40 pre-dose	0.8 mmHg Standard Deviation 7.6	-2.5 mmHg Standard Deviation 9.7	1.0 mmHg Standard Deviation 9.5	-1.0 mmHg Standard Deviation 7.2	-1.9 mmHg Standard Deviation 6.8
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 44 post dose	2.3 mmHg Standard Deviation 9.2	-1.3 mmHg Standard Deviation 7.6	-0.7 mmHg Standard Deviation 8.7	-1.4 mmHg Standard Deviation 8.1	-1.5 mmHg Standard Deviation 6.5
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Diastolic Blood Pressure Week 48	1.8 mmHg Standard Deviation 9.2	0.4 mmHg Standard Deviation 9.7	1.1 mmHg Standard Deviation 9.1	0.6 mmHg Standard Deviation 8.7	-0.8 mmHg Standard Deviation 6.4
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure 30 min post dose	0.8 mmHg Standard Deviation 8.1	0.5 mmHg Standard Deviation 9.7	-0.8 mmHg Standard Deviation 8.2	1.5 mmHg Standard Deviation 8.8	-2.5 mmHg Standard Deviation 9.7
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 1	-1.7 mmHg Standard Deviation 10.8	-1.3 mmHg Standard Deviation 10.0	1.7 mmHg Standard Deviation 12.9	-2.4 mmHg Standard Deviation 8.3	-1.6 mmHg Standard Deviation 11.0
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 2	-0.7 mmHg Standard Deviation 12.9	-0.2 mmHg Standard Deviation 9.8	-0.1 mmHg Standard Deviation 13.2	-2.7 mmHg Standard Deviation 8.2	-0.4 mmHg Standard Deviation 11.9
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 4 pre-dose	-2.6 mmHg Standard Deviation 11.4	-1.5 mmHg Standard Deviation 10.6	-1.0 mmHg Standard Deviation 13.0	-2.3 mmHg Standard Deviation 10.5	-2.7 mmHg Standard Deviation 11.2
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 4 post dose	-3.5 mmHg Standard Deviation 12.1	-0.6 mmHg Standard Deviation 10.4	-2.2 mmHg Standard Deviation 11.8	-0.6 mmHg Standard Deviation 9.1	-3.7 mmHg Standard Deviation 11.3
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 8 pre-dose	-2.1 mmHg Standard Deviation 13.1	-0.8 mmHg Standard Deviation 10.7	-1.1 mmHg Standard Deviation 11.3	-3.6 mmHg Standard Deviation 11.7	-1.3 mmHg Standard Deviation 10.4
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 20 pre-dose	-2.0 mmHg Standard Deviation 13.1	-3.2 mmHg Standard Deviation 12.5	-2.6 mmHg Standard Deviation 11.9	-5.4 mmHg Standard Deviation 9.7	-4.5 mmHg Standard Deviation 10.5
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 20 post dose	-1.9 mmHg Standard Deviation 14.5	-3.2 mmHg Standard Deviation 13.0	-3.7 mmHg Standard Deviation 12.2	-7.9 mmHg Standard Deviation 11.9	-4.4 mmHg Standard Deviation 9.9
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 24 pre-dose	-3.1 mmHg Standard Deviation 10.5	-1.1 mmHg Standard Deviation 9.5	-2.7 mmHg Standard Deviation 12.3	-3.6 mmHg Standard Deviation 10.1	-0.3 mmHg Standard Deviation 10.5
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 28 pre-dose	-0.1 mmHg Standard Deviation 11.4	-2.5 mmHg Standard Deviation 12.8	-2.5 mmHg Standard Deviation 13.1	0.4 mmHg Standard Deviation 11.6	-2.9 mmHg Standard Deviation 11.3
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 28 post dose	-1.1 mmHg Standard Deviation 12.1	-2.9 mmHg Standard Deviation 11.1	-2.6 mmHg Standard Deviation 12.4	-0.7 mmHg Standard Deviation 11.9	-4.6 mmHg Standard Deviation 11.2
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 32 pre-dose	-0.9 mmHg Standard Deviation 13.1	-1.5 mmHg Standard Deviation 13.3	-0.6 mmHg Standard Deviation 12.4	0.6 mmHg Standard Deviation 11.0	-3.7 mmHg Standard Deviation 12.4
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 32 post dose	-1.7 mmHg Standard Deviation 12.6	-2.2 mmHg Standard Deviation 11.6	0.3 mmHg Standard Deviation 12.5	-0.4 mmHg Standard Deviation 11.1	-4.8 mmHg Standard Deviation 10.6
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 36 pre-dose	-3.1 mmHg Standard Deviation 11.9	1.1 mmHg Standard Deviation 13.9	-0.2 mmHg Standard Deviation 13.6	-1.8 mmHg Standard Deviation 11.2	-3.2 mmHg Standard Deviation 11.1
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 36 post dose	-0.6 mmHg Standard Deviation 11.1	1.3 mmHg Standard Deviation 12.6	-0.5 mmHg Standard Deviation 12.4	-3.8 mmHg Standard Deviation 10.8	-3.8 mmHg Standard Deviation 11.4
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 40 pre-dose	-3.3 mmHg Standard Deviation 12.1	-3.1 mmHg Standard Deviation 11.4	-1.6 mmHg Standard Deviation 12.9	-4.0 mmHg Standard Deviation 9.5	-1.2 mmHg Standard Deviation 11.0
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 40 post dose	-2.3 mmHg Standard Deviation 11.7	-0.4 mmHg Standard Deviation 12.7	-1.2 mmHg Standard Deviation 13.8	-3.2 mmHg Standard Deviation 11.6	-2.2 mmHg Standard Deviation 9.6
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 44 pre-dose	-2.8 mmHg Standard Deviation 12.3	-2.8 mmHg Standard Deviation 9.9	0.0 mmHg Standard Deviation 13.1	-5.1 mmHg Standard Deviation 9.9	-3.9 mmHg Standard Deviation 10.3
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 44 post dose	-1.8 mmHg Standard Deviation 14.5	-1.2 mmHg Standard Deviation 9.5	-0.6 mmHg Standard Deviation 10.4	-4.6 mmHg Standard Deviation 10.3	-3.8 mmHg Standard Deviation 10.5
Changes From Baseline in Vital Signs During the Study (Diastolic Blood Pressure, Systolic Blood Pressure) Systolic Blood Pressure Week 48	-1.1 mmHg Standard Deviation 14.0	-0.1 mmHg Standard Deviation 12.5	-0.1 mmHg Standard Deviation 12.6	-2.8 mmHg Standard Deviation 11.5	-5.2 mmHg Standard Deviation 9.6

SECONDARY outcome

Timeframe: Baseline, 30 min and 1 hour post dose, Week 1, Week 2, pre- and post dose for the following Weeks: 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 and 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Pulse rate was measured in beats per minute (beats/min).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 12 pre-dose	1.1 beats/min Standard Deviation 10.2	-2.2 beats/min Standard Deviation 8.5	-2.9 beats/min Standard Deviation 10.5	-1.7 beats/min Standard Deviation 9.5	-1.1 beats/min Standard Deviation 8.4
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 1	2.9 beats/min Standard Deviation 8.3	-1.5 beats/min Standard Deviation 7.5	-0.7 beats/min Standard Deviation 7.1	0.6 beats/min Standard Deviation 8.9	-0.8 beats/min Standard Deviation 9.0
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 4 post dose	0.4 beats/min Standard Deviation 8.6	-2.6 beats/min Standard Deviation 6.6	-2.7 beats/min Standard Deviation 9.5	-0.5 beats/min Standard Deviation 9.4	-1.1 beats/min Standard Deviation 6.2
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 8 pre-dose	0.9 beats/min Standard Deviation 6.5	-0.6 beats/min Standard Deviation 8.0	-1.6 beats/min Standard Deviation 8.6	0.8 beats/min Standard Deviation 6.9	-1.3 beats/min Standard Deviation 8.2
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 8 post dose	-0.1 beats/min Standard Deviation 6.9	-1.3 beats/min Standard Deviation 8.6	-1.9 beats/min Standard Deviation 8.6	0.0 beats/min Standard Deviation 8.5	-2.3 beats/min Standard Deviation 8.3
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 16 post dose	-0.1 beats/min Standard Deviation 9.9	-3.5 beats/min Standard Deviation 5.5	-3.7 beats/min Standard Deviation 9.7	-2.1 beats/min Standard Deviation 9.8	-2.2 beats/min Standard Deviation 7.3
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 24 pre-dose	-0.5 beats/min Standard Deviation 7.9	-2.0 beats/min Standard Deviation 8.1	-2.8 beats/min Standard Deviation 10.4	-0.7 beats/min Standard Deviation 7.3	-1.2 beats/min Standard Deviation 7.8
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 28 pre-dose	1.9 beats/min Standard Deviation 9.7	-2.1 beats/min Standard Deviation 10.0	0.0 beats/min Standard Deviation 9.3	-0.5 beats/min Standard Deviation 11.2	0.2 beats/min Standard Deviation 8.3
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 36 pre-dose	0.7 beats/min Standard Deviation 8.5	0.2 beats/min Standard Deviation 7.5	-2.6 beats/min Standard Deviation 8.6	-2.6 beats/min Standard Deviation 10.2	-0.5 beats/min Standard Deviation 9.7
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 36 post dose	1.1 beats/min Standard Deviation 7.6	-0.8 beats/min Standard Deviation 8.2	-3.0 beats/min Standard Deviation 9.8	-2.5 beats/min Standard Deviation 8.2	-1.4 beats/min Standard Deviation 9.6
Changes From Baseline in Vital Signs During the Study (Pulse Rate) 30 min post dose	0.4 beats/min Standard Deviation 5.4	-0.8 beats/min Standard Deviation 5.6	-1.5 beats/min Standard Deviation 7.2	-2.3 beats/min Standard Deviation 7.5	-1.1 beats/min Standard Deviation 7.2
Changes From Baseline in Vital Signs During the Study (Pulse Rate) 1 hour post dose	0.3 beats/min Standard Deviation 6.7	1.0 beats/min Standard Deviation 11.3	-0.8 beats/min Standard Deviation 7.6	-0.8 beats/min Standard Deviation 8.1	-0.4 beats/min Standard Deviation 7.0
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 2	1.2 beats/min Standard Deviation 6.4	-1.7 beats/min Standard Deviation 5.7	-0.7 beats/min Standard Deviation 7.9	-1.0 beats/min Standard Deviation 9.1	-0.4 beats/min Standard Deviation 6.9
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 4 pre-dose	-0.2 beats/min Standard Deviation 5.3	-2.1 beats/min Standard Deviation 6.9	-1.9 beats/min Standard Deviation 8.1	0.1 beats/min Standard Deviation 9.8	-1.0 beats/min Standard Deviation 6.6
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 12 post dose	-0.6 beats/min Standard Deviation 8.8	-3.3 beats/min Standard Deviation 8.8	-3.6 beats/min Standard Deviation 9.4	-2.1 beats/min Standard Deviation 9.7	-2.0 beats/min Standard Deviation 7.8
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 16 pre-dose	-0.2 beats/min Standard Deviation 8.5	-2.1 beats/min Standard Deviation 5.8	-2.9 beats/min Standard Deviation 8.0	-1.9 beats/min Standard Deviation 10.1	-1.3 beats/min Standard Deviation 7.2
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 20 pre-dose	-0.1 beats/min Standard Deviation 10.3	-2.4 beats/min Standard Deviation 7.0	-1.7 beats/min Standard Deviation 10.3	0.0 beats/min Standard Deviation 9.0	-1.2 beats/min Standard Deviation 9.0
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 20 post dose	-0.7 beats/min Standard Deviation 6.8	-2.3 beats/min Standard Deviation 7.8	-2.1 beats/min Standard Deviation 9.7	-0.1 beats/min Standard Deviation 8.5	-1.3 beats/min Standard Deviation 8.9
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 24 post dose	-0.9 beats/min Standard Deviation 7.8	-2.9 beats/min Standard Deviation 8.5	-3.0 beats/min Standard Deviation 9.6	-1.3 beats/min Standard Deviation 6.9	-2.5 beats/min Standard Deviation 7.1
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 28 post dose	1.8 beats/min Standard Deviation 7.5	-3.0 beats/min Standard Deviation 9.4	-0.5 beats/min Standard Deviation 8.5	-0.8 beats/min Standard Deviation 10.0	0.0 beats/min Standard Deviation 7.5
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 32 pre-dose	3.3 beats/min Standard Deviation 10.0	-0.9 beats/min Standard Deviation 7.9	-2.0 beats/min Standard Deviation 9.2	-1.2 beats/min Standard Deviation 10.6	-0.3 beats/min Standard Deviation 7.8
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 32 post dose	3.3 beats/min Standard Deviation 8.4	-0.8 beats/min Standard Deviation 7.8	-3.0 beats/min Standard Deviation 9.5	-1.9 beats/min Standard Deviation 9.6	-2.0 beats/min Standard Deviation 8.8
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 40 pre-dose	2.7 beats/min Standard Deviation 10.3	-0.5 beats/min Standard Deviation 8.8	1.0 beats/min Standard Deviation 10.1	-1.7 beats/min Standard Deviation 7.6	2.0 beats/min Standard Deviation 9.4
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 40 post dose	0.9 beats/min Standard Deviation 8.3	-1.7 beats/min Standard Deviation 8.3	0.0 beats/min Standard Deviation 8.9	-2.0 beats/min Standard Deviation 8.4	0.5 beats/min Standard Deviation 9.1
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 44 pre-dose	2.2 beats/min Standard Deviation 8.9	-1.6 beats/min Standard Deviation 6.9	-0.4 beats/min Standard Deviation 10.1	-1.4 beats/min Standard Deviation 8.2	0.7 beats/min Standard Deviation 9.7
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 44 post dose	2.9 beats/min Standard Deviation 6.9	-1.7 beats/min Standard Deviation 8.0	-0.5 beats/min Standard Deviation 11.0	-2.8 beats/min Standard Deviation 7.7	-0.2 beats/min Standard Deviation 10.3
Changes From Baseline in Vital Signs During the Study (Pulse Rate) Week 48	2.0 beats/min Standard Deviation 8.9	-3.7 beats/min Standard Deviation 7.8	-2.5 beats/min Standard Deviation 10.4	-4.2 beats/min Standard Deviation 9.5	-3.1 beats/min Standard Deviation 9.5

SECONDARY outcome

Timeframe: Baseline, Week 12, Week 24, Week 36 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP. Overall number of participants analyzed include only those for whom body weight was measured and analyzed during the study.

Body weight was measured in kilograms.

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=41 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=38 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Body Weight During the Study Week 12	0.14 kilograms Standard Deviation 3.38	-0.87 kilograms Standard Deviation 3.12	0.21 kilograms Standard Deviation 1.78	-0.38 kilograms Standard Deviation 1.80	-0.04 kilograms Standard Deviation 2.39
Changes From Baseline in Body Weight During the Study Week 24	0.33 kilograms Standard Deviation 4.10	-0.03 kilograms Standard Deviation 3.48	-0.07 kilograms Standard Deviation 2.63	-0.13 kilograms Standard Deviation 2.37	-0.39 kilograms Standard Deviation 3.73
Changes From Baseline in Body Weight During the Study Week 36	0.32 kilograms Standard Deviation 5.15	-0.14 kilograms Standard Deviation 2.90	0.27 kilograms Standard Deviation 3.42	0.15 kilograms Standard Deviation 2.36	-0.04 kilograms Standard Deviation 4.19
Changes From Baseline in Body Weight During the Study Week 48	0.21 kilograms Standard Deviation 4.42	0.45 kilograms Standard Deviation 3.41	0.80 kilograms Standard Deviation 3.84	-0.14 kilograms Standard Deviation 3.32	0.11 kilograms Standard Deviation 4.24

SECONDARY outcome

Timeframe: Baseline, Week 12 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP. Overall number of participants analyzed include only those for whom electrocardiogram data was measured and analyzed during the study.

Electrocardiogram (ECG) intervals (QTcB= QT interval corrected for heart rate (Bazett's formula); QTcF= QT interval corrected for heart rate (Fridericia's formula)) were measured in milliseconds.

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=40 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=38 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=42 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=36 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR) QTcB Week 12	3.4 msec Standard Deviation 32.7	-2.8 msec Standard Deviation 29.9	-5.6 msec Standard Deviation 41.8	1.5 msec Standard Deviation 18.2	-1.9 msec Standard Deviation 31.4
Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR) QT Week 12	-2.0 msec Standard Deviation 46.6	1.7 msec Standard Deviation 34.0	9.5 msec Standard Deviation 21.4	3.8 msec Standard Deviation 25.6	11.5 msec Standard Deviation 80.8
Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR) RR Week 12	3.3 msec Standard Deviation 99.3	-22.5 msec Standard Deviation 212.6	75.8 msec Standard Deviation 179.3	11.0 msec Standard Deviation 125.1	-17.0 msec Standard Deviation 182.1
Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR) QTcB Week 48	-2.5 msec Standard Deviation 34.8	-5.8 msec Standard Deviation 36.5	-5.9 msec Standard Deviation 22.2	-4.7 msec Standard Deviation 21.0	-5.7 msec Standard Deviation 27.7
Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR) QTcF Week 12	4.5 msec Standard Deviation 27.5	-2.5 msec Standard Deviation 22.4	-2.2 msec Standard Deviation 14.2	-0.5 msec Standard Deviation 17.0	-3.0 msec Standard Deviation 18.8
Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR) QTcF Week 48	-0.1 msec Standard Deviation 30.7	-6.1 msec Standard Deviation 31.4	-0.2 msec Standard Deviation 15.6	-2.2 msec Standard Deviation 20.0	4.6 msec Standard Deviation 44.6
Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR) PR Week 12	-1.7 msec Standard Deviation 23.3	-1.0 msec Standard Deviation 23.7	-19.6 msec Standard Deviation 102.1	3.2 msec Standard Deviation 18.2	-9.5 msec Standard Deviation 32.3
Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR) PR Week 48	2.6 msec Standard Deviation 33.7	17.5 msec Standard Deviation 128.8	4.0 msec Standard Deviation 163.0	0.8 msec Standard Deviation 18.9	-2.8 msec Standard Deviation 26.5
Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR) QRS Week 12	2.6 msec Standard Deviation 22.3	-2.9 msec Standard Deviation 10.8	-1.8 msec Standard Deviation 7.6	-0.2 msec Standard Deviation 5.4	6.1 msec Standard Deviation 42.8
Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR) QRS Week 48	5.6 msec Standard Deviation 21.4	-1.5 msec Standard Deviation 16.1	-4.0 msec Standard Deviation 13.0	0.6 msec Standard Deviation 16.2	0.1 msec Standard Deviation 18.7
Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR) QT Week 48	-0.7 msec Standard Deviation 33.4	3.1 msec Standard Deviation 29.9	3.9 msec Standard Deviation 22.8	5.4 msec Standard Deviation 26.7	0.7 msec Standard Deviation 31.6
Changes From Baseline in Electrocardiogram (ECG) Intervals During the Study (QTcB, QTcF, PR, QRS, QT, RR) RR Week 48	-0.6 msec Standard Deviation 116.1	11.9 msec Standard Deviation 187.1	65.2 msec Standard Deviation 139.0	44.3 msec Standard Deviation 124.0	25.1 msec Standard Deviation 148.5

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils were measured in number of white blood cells per liter (10\^9/L).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 20	0.036 10^9 white blood cells per liter Standard Deviation 0.1038	0.026 10^9 white blood cells per liter Standard Deviation 0.1186	0.024 10^9 white blood cells per liter Standard Deviation 0.1157	-0.014 10^9 white blood cells per liter Standard Deviation 0.1228	0.038 10^9 white blood cells per liter Standard Deviation 0.0935
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 24	0.031 10^9 white blood cells per liter Standard Deviation 0.1301	0.013 10^9 white blood cells per liter Standard Deviation 0.0844	0.058 10^9 white blood cells per liter Standard Deviation 0.2111	-0.019 10^9 white blood cells per liter Standard Deviation 0.1238	0.037 10^9 white blood cells per liter Standard Deviation 0.1192
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 28	0.036 10^9 white blood cells per liter Standard Deviation 0.0986	0.018 10^9 white blood cells per liter Standard Deviation 0.0926	0.053 10^9 white blood cells per liter Standard Deviation 0.1826	-0.000 10^9 white blood cells per liter Standard Deviation 0.1213	0.025 10^9 white blood cells per liter Standard Deviation 0.0870
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 32	0.049 10^9 white blood cells per liter Standard Deviation 0.1502	0.033 10^9 white blood cells per liter Standard Deviation 0.0838	0.020 10^9 white blood cells per liter Standard Deviation 0.1418	0.024 10^9 white blood cells per liter Standard Deviation 0.1577	0.041 10^9 white blood cells per liter Standard Deviation 0.1141
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 1	0.000 10^9 white blood cells per liter Standard Deviation 0.0387	0.000 10^9 white blood cells per liter Standard Deviation 0.0329	-0.002 10^9 white blood cells per liter Standard Deviation 0.0408	0.007 10^9 white blood cells per liter Standard Deviation 0.0264	0.008 10^9 white blood cells per liter Standard Deviation 0.0350
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 4	0.002 10^9 white blood cells per liter Standard Deviation 0.0474	0.005 10^9 white blood cells per liter Standard Deviation 0.0324	-0.007 10^9 white blood cells per liter Standard Deviation 0.0463	0.005 10^9 white blood cells per liter Standard Deviation 0.0312	0.005 10^9 white blood cells per liter Standard Deviation 0.0312
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 8	-0.002 10^9 white blood cells per liter Standard Deviation 0.0353	0.000 10^9 white blood cells per liter Standard Deviation 0.0229	-0.005 10^9 white blood cells per liter Standard Deviation 0.0384	0.003 10^9 white blood cells per liter Standard Deviation 0.0367	0.002 10^9 white blood cells per liter Standard Deviation 0.0418
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 12	0.002 10^9 white blood cells per liter Standard Deviation 0.0353	0.003 10^9 white blood cells per liter Standard Deviation 0.0280	-0.002 10^9 white blood cells per liter Standard Deviation 0.0462	0.000 10^9 white blood cells per liter Standard Deviation 0.0329	0.010 10^9 white blood cells per liter Standard Deviation 0.0374
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 16	0.010 10^9 white blood cells per liter Standard Deviation 0.0431	0.005 10^9 white blood cells per liter Standard Deviation 0.0324	-0.007 10^9 white blood cells per liter Standard Deviation 0.0463	0.000 10^9 white blood cells per liter Standard Deviation 0.0329	0.008 10^9 white blood cells per liter Standard Deviation 0.0417
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 20	-0.003 10^9 white blood cells per liter Standard Deviation 0.0362	0.003 10^9 white blood cells per liter Standard Deviation 0.0362	0.000 10^9 white blood cells per liter Standard Deviation 0.0500	0.005 10^9 white blood cells per liter Standard Deviation 0.0329	0.000 10^9 white blood cells per liter Standard Deviation 0.0397
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 40	0.003 10^9 white blood cells per liter Standard Deviation 0.0506	0.005 10^9 white blood cells per liter Standard Deviation 0.0399	-0.010 10^9 white blood cells per liter Standard Deviation 0.0379	0.006 10^9 white blood cells per liter Standard Deviation 0.0343	0.000 10^9 white blood cells per liter Standard Deviation 0.0403
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 44	0.006 10^9 white blood cells per liter Standard Deviation 0.0410	0.003 10^9 white blood cells per liter Standard Deviation 0.0372	0.000 10^9 white blood cells per liter Standard Deviation 0.0387	0.006 10^9 white blood cells per liter Standard Deviation 0.0422	0.000 10^9 white blood cells per liter Standard Deviation 0.0338
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 8	0.024 10^9 white blood cells per liter Standard Deviation 0.0969	-0.003 10^9 white blood cells per liter Standard Deviation 0.0707	0.000 10^9 white blood cells per liter Standard Deviation 0.1000	0.008 10^9 white blood cells per liter Standard Deviation 0.0941	0.005 10^9 white blood cells per liter Standard Deviation 0.0669
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 12	0.020 10^9 white blood cells per liter Standard Deviation 0.0954	0.010 10^9 white blood cells per liter Standard Deviation 0.0882	0.002 10^9 white blood cells per liter Standard Deviation 0.0831	-0.026 10^9 white blood cells per liter Standard Deviation 0.1155	0.017 10^9 white blood cells per liter Standard Deviation 0.0704
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 40	0.050 10^9 white blood cells per liter Standard Deviation 0.1444	0.018 10^9 white blood cells per liter Standard Deviation 0.0865	0.018 10^9 white blood cells per liter Standard Deviation 0.0958	0.015 10^9 white blood cells per liter Standard Deviation 0.1971	0.039 10^9 white blood cells per liter Standard Deviation 0.1128
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 44	0.072 10^9 white blood cells per liter Standard Deviation 0.1523	0.019 10^9 white blood cells per liter Standard Deviation 0.0908	0.024 10^9 white blood cells per liter Standard Deviation 0.0994	-0.009 10^9 white blood cells per liter Standard Deviation 0.1798	0.006 10^9 white blood cells per liter Standard Deviation 0.0893
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 48	0.045 10^9 white blood cells per liter Standard Deviation 0.1811	0.006 10^9 white blood cells per liter Standard Deviation 0.0754	0.023 10^9 white blood cells per liter Standard Deviation 0.0891	0.009 10^9 white blood cells per liter Standard Deviation 0.2833	-0.005 10^9 white blood cells per liter Standard Deviation 0.0857
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 1	-0.271 10^9 white blood cells per liter Standard Deviation 1.1885	-0.597 10^9 white blood cells per liter Standard Deviation 1.1490	-0.656 10^9 white blood cells per liter Standard Deviation 1.2593	-1.029 10^9 white blood cells per liter Standard Deviation 1.6496	-0.285 10^9 white blood cells per liter Standard Deviation 1.6896
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 8	0.429 10^9 white blood cells per liter Standard Deviation 1.7036	-0.333 10^9 white blood cells per liter Standard Deviation 1.4014	-0.185 10^9 white blood cells per liter Standard Deviation 1.2889	-1.071 10^9 white blood cells per liter Standard Deviation 1.9639	-0.629 10^9 white blood cells per liter Standard Deviation 1.5489
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 16	-0.400 10^9 white blood cells per liter Standard Deviation 1.5616	-0.839 10^9 white blood cells per liter Standard Deviation 1.8179	-0.590 10^9 white blood cells per liter Standard Deviation 1.4668	-1.318 10^9 white blood cells per liter Standard Deviation 2.3324	-0.293 10^9 white blood cells per liter Standard Deviation 1.8427
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 20	-0.936 10^9 white blood cells per liter Standard Deviation 1.2756	-1.100 10^9 white blood cells per liter Standard Deviation 1.5599	-0.432 10^9 white blood cells per liter Standard Deviation 1.3032	-0.932 10^9 white blood cells per liter Standard Deviation 2.2832	-0.455 10^9 white blood cells per liter Standard Deviation 1.7116
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 24	-1.251 10^9 white blood cells per liter Standard Deviation 1.3888	-0.884 10^9 white blood cells per liter Standard Deviation 1.7768	-0.495 10^9 white blood cells per liter Standard Deviation 1.4216	-1.119 10^9 white blood cells per liter Standard Deviation 2.2807	-0.765 10^9 white blood cells per liter Standard Deviation 1.8691
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 36	-0.541 10^9 white blood cells per liter Standard Deviation 1.5971	-0.974 10^9 white blood cells per liter Standard Deviation 1.7389	-0.366 10^9 white blood cells per liter Standard Deviation 1.4549	-1.082 10^9 white blood cells per liter Standard Deviation 2.3389	-0.126 10^9 white blood cells per liter Standard Deviation 2.2565
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 40	-0.783 10^9 white blood cells per liter Standard Deviation 1.7693	-0.826 10^9 white blood cells per liter Standard Deviation 1.5942	-0.437 10^9 white blood cells per liter Standard Deviation 1.7878	-1.226 10^9 white blood cells per liter Standard Deviation 2.3856	-0.266 10^9 white blood cells per liter Standard Deviation 1.7976
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 44	-1.065 10^9 white blood cells per liter Standard Deviation 1.6070	-0.978 10^9 white blood cells per liter Standard Deviation 1.8151	-0.537 10^9 white blood cells per liter Standard Deviation 1.5641	-1.032 10^9 white blood cells per liter Standard Deviation 2.1585	-0.825 10^9 white blood cells per liter Standard Deviation 1.8917
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 1	-0.083 10^9 white blood cells per liter Standard Deviation 0.5074	-0.024 10^9 white blood cells per liter Standard Deviation 0.4142	0.044 10^9 white blood cells per liter Standard Deviation 0.5039	-0.017 10^9 white blood cells per liter Standard Deviation 0.4189	0.020 10^9 white blood cells per liter Standard Deviation 0.3006
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 2	0.105 10^9 white blood cells per liter Standard Deviation 0.3246	0.026 10^9 white blood cells per liter Standard Deviation 0.4137	0.021 10^9 white blood cells per liter Standard Deviation 0.6006	0.007 10^9 white blood cells per liter Standard Deviation 0.3643	0.161 10^9 white blood cells per liter Standard Deviation 0.4277
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 24	-0.041 10^9 white blood cells per liter Standard Deviation 0.3905	0.050 10^9 white blood cells per liter Standard Deviation 0.3630	0.048 10^9 white blood cells per liter Standard Deviation 0.4455	-0.036 10^9 white blood cells per liter Standard Deviation 0.3788	0.053 10^9 white blood cells per liter Standard Deviation 0.3974
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 44	-0.008 10^9 white blood cells per liter Standard Deviation 0.5390	0.105 10^9 white blood cells per liter Standard Deviation 0.4136	0.124 10^9 white blood cells per liter Standard Deviation 0.5366	0.115 10^9 white blood cells per liter Standard Deviation 0.4881	0.153 10^9 white blood cells per liter Standard Deviation 0.4462
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 2	0.076 10^9 white blood cells per liter Standard Deviation 0.1358	-0.011 10^9 white blood cells per liter Standard Deviation 0.1673	0.014 10^9 white blood cells per liter Standard Deviation 0.1897	-0.095 10^9 white blood cells per liter Standard Deviation 0.2701	-0.010 10^9 white blood cells per liter Standard Deviation 0.1882
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 16	-0.007 10^9 white blood cells per liter Standard Deviation 0.1629	-0.050 10^9 white blood cells per liter Standard Deviation 0.1673	-0.024 10^9 white blood cells per liter Standard Deviation 0.1265	-0.079 10^9 white blood cells per liter Standard Deviation 0.2384	-0.043 10^9 white blood cells per liter Standard Deviation 0.1752
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 20	-0.008 10^9 white blood cells per liter Standard Deviation 0.1783	-0.041 10^9 white blood cells per liter Standard Deviation 0.1534	-0.015 10^9 white blood cells per liter Standard Deviation 0.1509	-0.081 10^9 white blood cells per liter Standard Deviation 0.2448	-0.003 10^9 white blood cells per liter Standard Deviation 0.1899
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 24	-0.026 10^9 white blood cells per liter Standard Deviation 0.1292	-0.034 10^9 white blood cells per liter Standard Deviation 0.1361	0.003 10^9 white blood cells per liter Standard Deviation 0.1476	-0.056 10^9 white blood cells per liter Standard Deviation 0.2602	-0.027 10^9 white blood cells per liter Standard Deviation 0.1921
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 2	-0.026 10^9 white blood cells per liter Standard Deviation 1.1945	-0.418 10^9 white blood cells per liter Standard Deviation 1.1627	-0.337 10^9 white blood cells per liter Standard Deviation 1.3109	-0.880 10^9 white blood cells per liter Standard Deviation 1.8457	-0.537 10^9 white blood cells per liter Standard Deviation 1.3989
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 4	-0.102 10^9 white blood cells per liter Standard Deviation 1.0044	-0.405 10^9 white blood cells per liter Standard Deviation 1.1246	-0.290 10^9 white blood cells per liter Standard Deviation 1.3463	-0.924 10^9 white blood cells per liter Standard Deviation 1.9975	-0.732 10^9 white blood cells per liter Standard Deviation 1.4028
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 40	-1.006 10^9 white blood cells per liter Standard Deviation 1.7393	-0.992 10^9 white blood cells per liter Standard Deviation 1.4740	-0.575 10^9 white blood cells per liter Standard Deviation 1.9567	-1.229 10^9 white blood cells per liter Standard Deviation 2.4065	-0.495 10^9 white blood cells per liter Standard Deviation 1.5857
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 2	0.002 10^9 white blood cells per liter Standard Deviation 0.0269	0.003 10^9 white blood cells per liter Standard Deviation 0.0283	0.000 10^9 white blood cells per liter Standard Deviation 0.0488	0.000 10^9 white blood cells per liter Standard Deviation 0.0316	0.005 10^9 white blood cells per liter Standard Deviation 0.0384
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 24	0.000 10^9 white blood cells per liter Standard Deviation 0.0397	0.005 10^9 white blood cells per liter Standard Deviation 0.0324	-0.003 10^9 white blood cells per liter Standard Deviation 0.0530	0.008 10^9 white blood cells per liter Standard Deviation 0.0368	0.005 10^9 white blood cells per liter Standard Deviation 0.0389
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 28	0.005 10^9 white blood cells per liter Standard Deviation 0.0394	0.000 10^9 white blood cells per liter Standard Deviation 0.0329	0.008 10^9 white blood cells per liter Standard Deviation 0.0526	0.011 10^9 white blood cells per liter Standard Deviation 0.0323	0.005 10^9 white blood cells per liter Standard Deviation 0.0450
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 32	0.000 10^9 white blood cells per liter Standard Deviation 0.0324	0.005 10^9 white blood cells per liter Standard Deviation 0.0320	-0.010 10^9 white blood cells per liter Standard Deviation 0.0441	0.009 10^9 white blood cells per liter Standard Deviation 0.0379	0.010 10^9 white blood cells per liter Standard Deviation 0.0384
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 36	0.000 10^9 white blood cells per liter Standard Deviation 0.0408	0.003 10^9 white blood cells per liter Standard Deviation 0.0283	-0.002 10^9 white blood cells per liter Standard Deviation 0.0474	0.012 10^9 white blood cells per liter Standard Deviation 0.0415	0.013 10^9 white blood cells per liter Standard Deviation 0.0409
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Basophils Week 48	-0.005 10^9 white blood cells per liter Standard Deviation 0.0462	0.003 10^9 white blood cells per liter Standard Deviation 0.291	-0.010 10^9 white blood cells per liter Standard Deviation 0.0441	0.006 10^9 white blood cells per liter Standard Deviation 0.0354	0.000 10^9 white blood cells per liter Standard Deviation 0.0324
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 1	0.010 10^9 white blood cells per liter Standard Deviation 0.0860	0.016 10^9 white blood cells per liter Standard Deviation 0.0718	-0.002 10^9 white blood cells per liter Standard Deviation 0.0801	-0.005 10^9 white blood cells per liter Standard Deviation 0.0999	0.017 10^9 white blood cells per liter Standard Deviation 0.0636
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 2	0.005 10^9 white blood cells per liter Standard Deviation 0.0731	0.013 10^9 white blood cells per liter Standard Deviation 0.0777	0.002 10^9 white blood cells per liter Standard Deviation 0.0913	0.002 10^9 white blood cells per liter Standard Deviation 0.0880	0.029 10^9 white blood cells per liter Standard Deviation 0.0929
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 4	0.002 10^9 white blood cells per liter Standard Deviation 0.0987	0.016 10^9 white blood cells per liter Standard Deviation 0.0594	0.002 10^9 white blood cells per liter Standard Deviation 0.0780	0.005 10^9 white blood cells per liter Standard Deviation 0.0999	0.027 10^9 white blood cells per liter Standard Deviation 0.0895
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 16	0.045 10^9 white blood cells per liter Standard Deviation 0.1253	0.021 10^9 white blood cells per liter Standard Deviation 0.0935	0.010 10^9 white blood cells per liter Standard Deviation 0.0759	-0.005 10^9 white blood cells per liter Standard Deviation 0.1559	0.033 10^9 white blood cells per liter Standard Deviation 0.0829
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Eosinophils Week 36	0.054 10^9 white blood cells per liter Standard Deviation 0.1726	0.018 10^9 white blood cells per liter Standard Deviation 0.0955	0.022 10^9 white blood cells per liter Standard Deviation 0.0909	0.027 10^9 white blood cells per liter Standard Deviation 0.1526	0.015 10^9 white blood cells per liter Standard Deviation 0.0961
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 2	0.157 10^9 white blood cells per liter Standard Deviation 1.3195	-0.131 10^9 white blood cells per liter Standard Deviation 2.1769	-0.309 10^9 white blood cells per liter Standard Deviation 1.3735	-0.954 10^9 white blood cells per liter Standard Deviation 2.0441	-0.322 10^9 white blood cells per liter Standard Deviation 1.5501
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 4	-0.049 10^9 white blood cells per liter Standard Deviation 1.1938	-0.411 10^9 white blood cells per liter Standard Deviation 1.1988	-0.336 10^9 white blood cells per liter Standard Deviation 1.5088	-1.017 10^9 white blood cells per liter Standard Deviation 1.9397	-0.656 10^9 white blood cells per liter Standard Deviation 1.4264
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 12	0.190 10^9 white blood cells per liter Standard Deviation 1.6223	-0.438 10^9 white blood cells per liter Standard Deviation 1.3854	-0.495 10^9 white blood cells per liter Standard Deviation 1.6904	-0.997 10^9 white blood cells per liter Standard Deviation 2.1806	-0.634 10^9 white blood cells per liter Standard Deviation 1.6084
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 28	-0.700 10^9 white blood cells per liter Standard Deviation 1.8180	-0.316 10^9 white blood cells per liter Standard Deviation 2.3086	-0.100 10^9 white blood cells per liter Standard Deviation 1.4942	-0.894 10^9 white blood cells per liter Standard Deviation 1.7119	-0.342 10^9 white blood cells per liter Standard Deviation 1.5683
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 32	-0.762 10^9 white blood cells per liter Standard Deviation 1.4273	-0.862 10^9 white blood cells per liter Standard Deviation 2.0091	-0.330 10^9 white blood cells per liter Standard Deviation 1.5750	-0.918 10^9 white blood cells per liter Standard Deviation 2.6184	-0.505 10^9 white blood cells per liter Standard Deviation 1.4800
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Leukocytes Week 48	-0.739 10^9 white blood cells per liter Standard Deviation 1.7774	-0.869 10^9 white blood cells per liter Standard Deviation 1.7109	-0.473 10^9 white blood cells per liter Standard Deviation 1.7104	-1.225 10^9 white blood cells per liter Standard Deviation 2.5952	-0.777 10^9 white blood cells per liter Standard Deviation 1.8593
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 4	0.037 10^9 white blood cells per liter Standard Deviation 0.4386	0.024 10^9 white blood cells per liter Standard Deviation 0.3259	0.010 10^9 white blood cells per liter Standard Deviation 0.6003	-0.032 10^9 white blood cells per liter Standard Deviation 0.3996	0.095 10^9 white blood cells per liter Standard Deviation 0.3263
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 8	0.120 10^9 white blood cells per liter Standard Deviation 0.3776	0.054 10^9 white blood cells per liter Standard Deviation 0.3783	0.063 10^9 white blood cells per liter Standard Deviation 0.5928	0.053 10^9 white blood cells per liter Standard Deviation 0.4980	0.129 10^9 white blood cells per liter Standard Deviation 0.3939
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 12	0.041 10^9 white blood cells per liter Standard Deviation 0.3647	0.051 10^9 white blood cells per liter Standard Deviation 0.4167	0.000 10^9 white blood cells per liter Standard Deviation 0.5640	-0.047 10^9 white blood cells per liter Standard Deviation 0.3703	0.061 10^9 white blood cells per liter Standard Deviation 0.3301
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 16	0.052 10^9 white blood cells per liter Standard Deviation 0.5567	0.071 10^9 white blood cells per liter Standard Deviation 0.3571	0.026 10^9 white blood cells per liter Standard Deviation 0.5539	-0.029 10^9 white blood cells per liter Standard Deviation 0.4991	0.135 10^9 white blood cells per liter Standard Deviation 0.4197
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 20	0.003 10^9 white blood cells per liter Standard Deviation 0.4934	0.008 10^9 white blood cells per liter Standard Deviation 0.3970	0.149 10^9 white blood cells per liter Standard Deviation 0.4675	-0.035 10^9 white blood cells per liter Standard Deviation 0.4566	0.126 10^9 white blood cells per liter Standard Deviation 0.4216
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 28	0.036 10^9 white blood cells per liter Standard Deviation 0.5869	0.105 10^9 white blood cells per liter Standard Deviation 0.3594	0.210 10^9 white blood cells per liter Standard Deviation 0.5999	0.103 10^9 white blood cells per liter Standard Deviation 0.5544	0.172 10^9 white blood cells per liter Standard Deviation 0.3776
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 32	-0.000 10^9 white blood cells per liter Standard Deviation 0.5109	0.103 10^9 white blood cells per liter Standard Deviation 0.4233	0.083 10^9 white blood cells per liter Standard Deviation 0.6524	0.112 10^9 white blood cells per liter Standard Deviation 0.5056	0.146 10^9 white blood cells per liter Standard Deviation 0.3966
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 36	0.078 10^9 white blood cells per liter Standard Deviation 0.4894	0.039 10^9 white blood cells per liter Standard Deviation 0.4227	0.134 10^9 white blood cells per liter Standard Deviation 0.5673	0.103 10^9 white blood cells per liter Standard Deviation 0.5491	0.118 10^9 white blood cells per liter Standard Deviation 0.3810
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 40	0.139 10^9 white blood cells per liter Standard Deviation 0.4871	0.168 10^9 white blood cells per liter Standard Deviation 0.4281	0.120 10^9 white blood cells per liter Standard Deviation 0.6018	0.038 10^9 white blood cells per liter Standard Deviation 0.4335	0.176 10^9 white blood cells per liter Standard Deviation 0.3709
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Lymphocytes Week 48	0.066 10^9 white blood cells per liter Standard Deviation 0.5313	0.103 10^9 white blood cells per liter Standard Deviation 0.3645	0.078 10^9 white blood cells per liter Standard Deviation 0.5041	0.019 10^9 white blood cells per liter Standard Deviation 0.3763	0.072 10^9 white blood cells per liter Standard Deviation 0.3755
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 1	0.007 10^9 white blood cells per liter Standard Deviation 0.2184	-0.008 10^9 white blood cells per liter Standard Deviation 0.1477	-0.012 10^9 white blood cells per liter Standard Deviation 0.1679	-0.088 10^9 white blood cells per liter Standard Deviation 0.2315	-0.027 10^9 white blood cells per liter Standard Deviation 0.1724
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 4	0.032 10^9 white blood cells per liter Standard Deviation 0.1588	-0.021 10^9 white blood cells per liter Standard Deviation 0.1473	-0.040 10^9 white blood cells per liter Standard Deviation 0.1862	-0.066 10^9 white blood cells per liter Standard Deviation 0.2404	-0.085 10^9 white blood cells per liter Standard Deviation 0.1459
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 8	0.059 10^9 white blood cells per liter Standard Deviation 0.1910	-0.041 10^9 white blood cells per liter Standard Deviation 0.1743	0.005 10^9 white blood cells per liter Standard Deviation 0.1580	-0.103 10^9 white blood cells per liter Standard Deviation 0.2520	-0.071 10^9 white blood cells per liter Standard Deviation 0.1834
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 12	0.020 10^9 white blood cells per liter Standard Deviation 0.1913	-0.031 10^9 white blood cells per liter Standard Deviation 0.1608	-0.033 10^9 white blood cells per liter Standard Deviation 0.1686	-0.105 10^9 white blood cells per liter Standard Deviation 0.2630	-0.059 10^9 white blood cells per liter Standard Deviation 0.1414
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 28	0.026 10^9 white blood cells per liter Standard Deviation 0.2087	0.042 10^9 white blood cells per liter Standard Deviation 0.1981	0.055 10^9 white blood cells per liter Standard Deviation 0.1724	-0.029 10^9 white blood cells per liter Standard Deviation 0.2729	-0.012 10^9 white blood cells per liter Standard Deviation 0.1911
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 32	0.064 10^9 white blood cells per liter Standard Deviation 0.2356	-0.005 10^9 white blood cells per liter Standard Deviation 0.1731	-0.003 10^9 white blood cells per liter Standard Deviation 0.1271	-0.035 10^9 white blood cells per liter Standard Deviation 0.2684	0.010 10^9 white blood cells per liter Standard Deviation 0.1744
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 36	0.054 10^9 white blood cells per liter Standard Deviation 0.1626	-0.024 10^9 white blood cells per liter Standard Deviation 0.1792	0.032 10^9 white blood cells per liter Standard Deviation 0.1404	-0.036 10^9 white blood cells per liter Standard Deviation 0.2644	0.049 10^9 white blood cells per liter Standard Deviation 0.2327
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 40	0.053 10^9 white blood cells per liter Standard Deviation 0.1647	0.008 10^9 white blood cells per liter Standard Deviation 0.1323	0.020 10^9 white blood cells per liter Standard Deviation 0.1636	-0.059 10^9 white blood cells per liter Standard Deviation 0.2830	-0.018 10^9 white blood cells per liter Standard Deviation 0.1504
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 44	0.019 10^9 white blood cells per liter Standard Deviation 0.1939	-0.008 10^9 white blood cells per liter Standard Deviation 0.1588	0.044 10^9 white blood cells per liter Standard Deviation 0.1644	-0.032 10^9 white blood cells per liter Standard Deviation 0.2446	-0.019 10^9 white blood cells per liter Standard Deviation 0.2202
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Monocytes Week 48	0.021 10^9 white blood cells per liter Standard Deviation 0.2145	0.000 10^9 white blood cells per liter Standard Deviation 0.1707	-0.013 10^9 white blood cells per liter Standard Deviation 0.1399	-0.078 10^9 white blood cells per liter Standard Deviation 0.2511	-0.077 10^9 white blood cells per liter Standard Deviation 0.1709
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 1	-0.200 10^9 white blood cells per liter Standard Deviation 1.0959	-0.558 10^9 white blood cells per liter Standard Deviation 0.9627	-0.693 10^9 white blood cells per liter Standard Deviation 1.2971	-0.934 10^9 white blood cells per liter Standard Deviation 1.4768	-0.325 10^9 white blood cells per liter Standard Deviation 1.5720
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 8	0.249 10^9 white blood cells per liter Standard Deviation 1.5358	-0.346 10^9 white blood cells per liter Standard Deviation 1.2640	-0.256 10^9 white blood cells per liter Standard Deviation 1.3898	-1.021 10^9 white blood cells per liter Standard Deviation 1.7129	-0.717 10^9 white blood cells per liter Standard Deviation 1.4589
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 12	0.117 10^9 white blood cells per liter Standard Deviation 1.5103	-0.456 10^9 white blood cells per liter Standard Deviation 1.1227	-0.458 10^9 white blood cells per liter Standard Deviation 1.6879	-0.832 10^9 white blood cells per liter Standard Deviation 2.2192	-0.673 10^9 white blood cells per liter Standard Deviation 1.3887
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 16	-0.490 10^9 white blood cells per liter Standard Deviation 1.6866	-0.879 10^9 white blood cells per liter Standard Deviation 1.5752	-0.617 10^9 white blood cells per liter Standard Deviation 1.6027	-1.203 10^9 white blood cells per liter Standard Deviation 2.2840	-0.448 10^9 white blood cells per liter Standard Deviation 1.6816
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 20	-0.972 10^9 white blood cells per liter Standard Deviation 1.2085	-1.069 10^9 white blood cells per liter Standard Deviation 1.4219	-0.595 10^9 white blood cells per liter Standard Deviation 1.4319	-0.827 10^9 white blood cells per liter Standard Deviation 2.2663	-0.618 10^9 white blood cells per liter Standard Deviation 1.5716
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 24	-1.210 10^9 white blood cells per liter Standard Deviation 1.4067	-0.895 10^9 white blood cells per liter Standard Deviation 1.6288	-0.593 10^9 white blood cells per liter Standard Deviation 1.5309	-1.011 10^9 white blood cells per liter Standard Deviation 2.2968	-0.850 10^9 white blood cells per liter Standard Deviation 1.6461
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 28	-0.774 10^9 white blood cells per liter Standard Deviation 1.8189	-0.484 10^9 white blood cells per liter Standard Deviation 2.2620	-0.555 10^9 white blood cells per liter Standard Deviation 1.2608	-0.949 10^9 white blood cells per liter Standard Deviation 1.7676	-0.568 10^9 white blood cells per liter Standard Deviation 1.3889
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 32	-0.869 10^9 white blood cells per liter Standard Deviation 1.2796	-0.969 10^9 white blood cells per liter Standard Deviation 1.8241	-0.433 10^9 white blood cells per liter Standard Deviation 1.7889	-1.038 10^9 white blood cells per liter Standard Deviation 2.4800	-0.718 10^9 white blood cells per liter Standard Deviation 1.4299
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 36	-0.722 10^9 white blood cells per liter Standard Deviation 1.6422	-0.992 10^9 white blood cells per liter Standard Deviation 1.6583	-0.541 10^9 white blood cells per liter Standard Deviation 1.5519	-1.185 10^9 white blood cells per liter Standard Deviation 2.1881	-0.354 10^9 white blood cells per liter Standard Deviation 2.1441
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 44	-0.978 10^9 white blood cells per liter Standard Deviation 1.2444	-1.086 10^9 white blood cells per liter Standard Deviation 1.6049	-0.717 10^9 white blood cells per liter Standard Deviation 1.6966	-1.109 10^9 white blood cells per liter Standard Deviation 2.2673	-0.983 10^9 white blood cells per liter Standard Deviation 1.6556
Changes From Baseline in Hematology Parameters During the Study (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils) Neutrophils Week 48	-0.861 10^9 white blood cells per liter Standard Deviation 1.6858	-0.939 10^9 white blood cells per liter Standard Deviation 1.5670	-0.558 10^9 white blood cells per liter Standard Deviation 1.7944	-1.178 10^9 white blood cells per liter Standard Deviation 2.6503	-0.805 10^9 white blood cells per liter Standard Deviation 1.6631

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Erythrocytes mean corpuscular hemoglobin (HGB) concentration and hemoglobin were measured in grams per liter (g/L).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 24	1.000 g/L Standard Deviation 10.9232	4.132 g/L Standard Deviation 10.3849	-0.625 g/L Standard Deviation 14.6685	4.583 g/L Standard Deviation 11.3121	4.250 g/L Standard Deviation 13.4064
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 12	-7.927 g/L Standard Deviation 14.6704	-3.179 g/L Standard Deviation 13.4122	-3.907 g/L Standard Deviation 11.5404	-2.684 g/L Standard Deviation 9.4099	1.732 g/L Standard Deviation 13.3959
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 16	-6.286 g/L Standard Deviation 12.3393	-3.000 g/L Standard Deviation 14.5751	-5.262 g/L Standard Deviation 12.1917	-1.026 g/L Standard Deviation 11.6816	-0.700 g/L Standard Deviation 16.1026
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 20	-5.050 g/L Standard Deviation 12.8102	0.923 g/L Standard Deviation 11.8108	-1.902 g/L Standard Deviation 12.8078	0.919 g/L Standard Deviation 8.7349	0.200 g/L Standard Deviation 16.1725
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 32	6.308 g/L Standard Deviation 9.7796	10.231 g/L Standard Deviation 9.5957	4.850 g/L Standard Deviation 11.3692	7.971 g/L Standard Deviation 12.3497	10.462 g/L Standard Deviation 12.9855
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 40	3.108 g/L Standard Deviation 9.8736	8.237 g/L Standard Deviation 12.0706	4.976 g/L Standard Deviation 11.5639	9.088 g/L Standard Deviation 11.5480	9.079 g/L Standard Deviation 11.5393
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 44	6.297 g/L Standard Deviation 10.6975	7.289 g/L Standard Deviation 12.6254	3.415 g/L Standard Deviation 12.6293	6.353 g/L Standard Deviation 14.3038	9.278 g/L Standard Deviation 12.8076
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 48	5.079 g/L Standard Deviation 10.4916	7.216 g/L Standard Deviation 9.3812	2.122 g/L Standard Deviation 11.8769	5.394 g/L Standard Deviation 12.9300	8.250 g/L Standard Deviation 11.3448
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 1	-4.854 g/L Standard Deviation 5.6726	0.000 g/L Standard Deviation 5.6569	1.302 g/L Standard Deviation 5.1480	0.512 g/L Standard Deviation 6.0462	-0.875 g/L Standard Deviation 4.8368
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 2	-4.810 g/L Standard Deviation 6.5154	-0.359 g/L Standard Deviation 5.2339	0.070 g/L Standard Deviation 6.5915	-1.561 g/L Standard Deviation 6.7047	0.317 g/L Standard Deviation 5.3499
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 12	-5.220 g/L Standard Deviation 6.7879	0.692 g/L Standard Deviation 7.7601	2.488 g/L Standard Deviation 7.6512	0.868 g/L Standard Deviation 7.3344	2.488 g/L Standard Deviation 8.2344
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 16	-1.619 g/L Standard Deviation 6.4768	2.579 g/L Standard Deviation 8.3880	1.524 g/L Standard Deviation 8.7853	1.737 g/L Standard Deviation 7.3547	3.125 g/L Standard Deviation 7.7400
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 32	-0.282 g/L Standard Deviation 8.2684	4.487 g/L Standard Deviation 8.3094	4.300 g/L Standard Deviation 9.4032	2.118 g/L Standard Deviation 7.4254	5.615 g/L Standard Deviation 8.6378
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 36	0.947 g/L Standard Deviation 9.1738	6.053 g/L Standard Deviation 8.1405	4.293 g/L Standard Deviation 9.5766	3.818 g/L Standard Deviation 7.3334	4.949 g/L Standard Deviation 8.4851
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 44	1.486 g/L Standard Deviation 10.1040	5.000 g/L Standard Deviation 9.2998	3.659 g/L Standard Deviation 9.1750	4.912 g/L Standard Deviation 8.5895	4.722 g/L Standard Deviation 8.5511
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 4	-3.927 g/L Standard Deviation 10.0633	1.474 g/L Standard Deviation 10.5849	-2.500 g/L Standard Deviation 11.5045	-0.878 g/L Standard Deviation 9.4026	1.756 g/L Standard Deviation 11.8697
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 8	-5.195 g/L Standard Deviation 11.7158	-1.897 g/L Standard Deviation 11.3249	-3.780 g/L Standard Deviation 10.7576	-3.079 g/L Standard Deviation 10.7033	0.610 g/L Standard Deviation 12.7493
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 28	2.179 g/L Standard Deviation 10.3285	4.658 g/L Standard Deviation 9.6906	1.707 g/L Standard Deviation 9.9505	4.400 g/L Standard Deviation 13.7524	6.150 g/L Standard Deviation 12.5382
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 36	5.500 g/L Standard Deviation 9.7779	10.921 g/L Standard Deviation 10.2229	2.732 g/L Standard Deviation 12.4097	6.788 g/L Standard Deviation 12.2034	9.462 g/L Standard Deviation 12.7998
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 4	-4.390 g/L Standard Deviation 7.5162	0.895 g/L Standard Deviation 7.6434	0.881 g/L Standard Deviation 6.4551	0.512 g/L Standard Deviation 5.7189	1.195 g/L Standard Deviation 5.8916
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 8	-4.561 g/L Standard Deviation 7.0995	0.308 g/L Standard Deviation 7.0865	2.195 g/L Standard Deviation 7.7628	0.553 g/L Standard Deviation 6.8010	1.195 g/L Standard Deviation 7.4439
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 20	-0.400 g/L Standard Deviation 7.3233	2.667 g/L Standard Deviation 8.6764	2.268 g/L Standard Deviation 6.9822	1.892 g/L Standard Deviation 7.6186	2.925 g/L Standard Deviation 7.7207
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 24	0.564 g/L Standard Deviation 8.1879	3.658 g/L Standard Deviation 9.0622	4.075 g/L Standard Deviation 8.0714	2.000 g/L Standard Deviation 6.6462	3.425 g/L Standard Deviation 6.2834
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 28	-1.513 g/L Standard Deviation 8.0259	3.342 g/L Standard Deviation 8.9511	3.122 g/L Standard Deviation 8.6261	0.857 g/L Standard Deviation 7.2645	3.400 g/L Standard Deviation 8.6730
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 40	1.432 g/L Standard Deviation 9.1090	5.868 g/L Standard Deviation 8.7863	4.317 g/L Standard Deviation 9.6552	3.618 g/L Standard Deviation 7.8277	4.132 g/L Standard Deviation 7.7987
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Hemoglobin Week 48	2.474 g/L Standard Deviation 9.7002	5.270 g/L Standard Deviation 9.1974	3.780 g/L Standard Deviation 9.9210	4.030 g/L Standard Deviation 9.2550	4.725 g/L Standard Deviation 7.3554
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 1	-2.293 g/L Standard Deviation 8.4594	0.789 g/L Standard Deviation 8.9719	-1.860 g/L Standard Deviation 8.0551	0.927 g/L Standard Deviation 9.1088	1.200 g/L Standard Deviation 12.2395
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin) Ery. mean corpuscular HGB Week 2	-2.310 g/L Standard Deviation 7.9923	2.564 g/L Standard Deviation 9.8216	0.465 g/L Standard Deviation 8.4778	0.707 g/L Standard Deviation 8.6263	2.854 g/L Standard Deviation 10.1822

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 1	-0.073 picograms (pg) Standard Deviation 0.4980	0.058 picograms (pg) Standard Deviation 0.4624	-0.049 picograms (pg) Standard Deviation 0.4050	0.073 picograms (pg) Standard Deviation 0.3975	-0.055 picograms (pg) Standard Deviation 0.4455
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 24	-0.249 picograms (pg) Standard Deviation 1.0443	0.108 picograms (pg) Standard Deviation 0.9947	-0.057 picograms (pg) Standard Deviation 1.1804	-0.097 picograms (pg) Standard Deviation 0.7284	-0.007 picograms (pg) Standard Deviation 1.2338
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 44	0.097 picograms (pg) Standard Deviation 1.3103	0.129 picograms (pg) Standard Deviation 0.8742	-0.080 picograms (pg) Standard Deviation 1.1771	-0.159 picograms (pg) Standard Deviation 0.7480	0.108 picograms (pg) Standard Deviation 1.2532
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 2	-0.050 picograms (pg) Standard Deviation 0.3890	0.126 picograms (pg) Standard Deviation 0.5149	0.023 picograms (pg) Standard Deviation 0.4225	0.066 picograms (pg) Standard Deviation 0.4357	0.085 picograms (pg) Standard Deviation 0.4287
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 4	-0.112 picograms (pg) Standard Deviation 0.5501	0.089 picograms (pg) Standard Deviation 0.5584	0.060 picograms (pg) Standard Deviation 0.5910	0.012 picograms (pg) Standard Deviation 0.4691	0.066 picograms (pg) Standard Deviation 0.6085
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 8	-0.110 picograms (pg) Standard Deviation 0.6778	0.141 picograms (pg) Standard Deviation 0.6801	0.007 picograms (pg) Standard Deviation 0.5926	0.034 picograms (pg) Standard Deviation 0.6851	0.095 picograms (pg) Standard Deviation 0.7994
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 12	-0.285 picograms (pg) Standard Deviation 0.6770	0.023 picograms (pg) Standard Deviation 0.7253	0.091 picograms (pg) Standard Deviation 0.8358	-0.132 picograms (pg) Standard Deviation 0.8335	0.039 picograms (pg) Standard Deviation 1.0454
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 16	-0.233 picograms (pg) Standard Deviation 0.7281	0.097 picograms (pg) Standard Deviation 0.8824	0.014 picograms (pg) Standard Deviation 0.9236	-0.118 picograms (pg) Standard Deviation 0.8440	-0.067 picograms (pg) Standard Deviation 1.1713
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 20	-0.290 picograms (pg) Standard Deviation 0.8145	-0.033 picograms (pg) Standard Deviation 0.9172	0.029 picograms (pg) Standard Deviation 0.9819	-0.035 picograms (pg) Standard Deviation 0.7013	0.075 picograms (pg) Standard Deviation 1.0824
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 28	-0.103 picograms (pg) Standard Deviation 1.0101	0.029 picograms (pg) Standard Deviation 0.7241	-0.122 picograms (pg) Standard Deviation 1.1130	-0.211 picograms (pg) Standard Deviation 0.8277	0.020 picograms (pg) Standard Deviation 1.2950
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 32	0.003 picograms (pg) Standard Deviation 1.2619	0.297 picograms (pg) Standard Deviation 0.8561	0.058 picograms (pg) Standard Deviation 1.1522	0.026 picograms (pg) Standard Deviation 0.7684	0.167 picograms (pg) Standard Deviation 1.2472
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 36	-0.082 picograms (pg) Standard Deviation 1.3242	0.237 picograms (pg) Standard Deviation 0.8722	-0.093 picograms (pg) Standard Deviation 1.0792	-0.248 picograms (pg) Standard Deviation 0.8581	0.118 picograms (pg) Standard Deviation 1.1473
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 40	-0.170 picograms (pg) Standard Deviation 1.3453	0.134 picograms (pg) Standard Deviation 0.8960	-0.134 picograms (pg) Standard Deviation 1.2095	-0.147 picograms (pg) Standard Deviation 0.8645	0.034 picograms (pg) Standard Deviation 1.0839
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Hemoglobin (HGB)) Week 48	0.137 picograms (pg) Standard Deviation 1.4139	0.178 picograms (pg) Standard Deviation 0.9369	-0.120 picograms (pg) Standard Deviation 1.1279	-0.030 picograms (pg) Standard Deviation 0.7888	0.140 picograms (pg) Standard Deviation 1.2161

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Erythrocytes mean corpuscular volume was measured in femtolitres (fL).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 8	1.163 femtolitres (fL) Standard Deviation 3.6524	0.938 femtolitres (fL) Standard Deviation 2.9445	1.110 femtolitres (fL) Standard Deviation 3.0283	0.916 femtolitres (fL) Standard Deviation 3.0058	0.090 femtolitres (fL) Standard Deviation 3.5125
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 12	1.478 femtolitres (fL) Standard Deviation 3.9560	0.951 femtolitres (fL) Standard Deviation 3.4617	1.367 femtolitres (fL) Standard Deviation 3.8471	0.342 femtolitres (fL) Standard Deviation 3.1129	-0.390 femtolitres (fL) Standard Deviation 3.3907
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 24	-1.033 femtolitres (fL) Standard Deviation 2.9007	-0.858 femtolitres (fL) Standard Deviation 2.1793	0.143 femtolitres (fL) Standard Deviation 4.9985	-1.522 femtolitres (fL) Standard Deviation 3.1692	-1.195 femtolitres (fL) Standard Deviation 3.5759
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 28	-0.910 femtolitres (fL) Standard Deviation 2.6477	-1.184 femtolitres (fL) Standard Deviation 2.3264	-0.754 femtolitres (fL) Standard Deviation 3.3662	-1.854 femtolitres (fL) Standard Deviation 3.6605	-1.638 femtolitres (fL) Standard Deviation 3.3447
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 36	-1.724 femtolitres (fL) Standard Deviation 3.1037	-2.266 femtolitres (fL) Standard Deviation 2.3516	-0.912 femtolitres (fL) Standard Deviation 3.9627	-2.558 femtolitres (fL) Standard Deviation 3.8468	-2.236 femtolitres (fL) Standard Deviation 3.2869
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 48	-0.942 femtolitres (fL) Standard Deviation 3.5913	-1.492 femtolitres (fL) Standard Deviation 2.5065	-0.846 femtolitres (fL) Standard Deviation 3.1243	-1.527 femtolitres (fL) Standard Deviation 3.6540	-1.788 femtolitres (fL) Standard Deviation 3.5554
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 1	0.422 femtolitres (fL) Standard Deviation 1.8855	-0.087 femtolitres (fL) Standard Deviation 1.9540	0.386 femtolitres (fL) Standard Deviation 2.2542	-0.017 femtolitres (fL) Standard Deviation 2.1066	-0.510 femtolitres (fL) Standard Deviation 2.7686
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 2	0.450 femtolitres (fL) Standard Deviation 1.8867	-0.362 femtolitres (fL) Standard Deviation 2.1689	-0.021 femtolitres (fL) Standard Deviation 1.8767	-0.039 femtolitres (fL) Standard Deviation 2.3876	-0.549 femtolitres (fL) Standard Deviation 2.5751
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 4	0.829 femtolitres (fL) Standard Deviation 2.3409	-0.163 femtolitres (fL) Standard Deviation 2.4631	0.945 femtolitres (fL) Standard Deviation 3.2325	0.354 femtolitres (fL) Standard Deviation 2.8851	-0.259 femtolitres (fL) Standard Deviation 2.5328
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 16	1.107 femtolitres (fL) Standard Deviation 3.4022	1.168 femtolitres (fL) Standard Deviation 3.7760	1.571 femtolitres (fL) Standard Deviation 4.3326	-0.016 femtolitres (fL) Standard Deviation 3.6944	0.048 femtolitres (fL) Standard Deviation 4.4345
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 20	0.497 femtolitres (fL) Standard Deviation 3.5197	-0.349 femtolitres (fL) Standard Deviation 2.8975	0.649 femtolitres (fL) Standard Deviation 3.7758	-0.338 femtolitres (fL) Standard Deviation 2.5959	0.202 femtolitres (fL) Standard Deviation 4.2993
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 32	-1.654 femtolitres (fL) Standard Deviation 2.7565	-1.851 femtolitres (fL) Standard Deviation 2.4024	-1.075 femtolitres (fL) Standard Deviation 3.5390	-2.071 femtolitres (fL) Standard Deviation 3.7652	-2.351 femtolitres (fL) Standard Deviation 3.1052
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 40	-1.386 femtolitres (fL) Standard Deviation 2.8575	-1.882 femtolitres (fL) Standard Deviation 3.1285	-1.698 femtolitres (fL) Standard Deviation 3.0263	-2.885 femtolitres (fL) Standard Deviation 3.1443	-2.421 femtolitres (fL) Standard Deviation 2.9445
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes Mean Corpuscular Volume) Week 44	-1.405 femtolitres (fL) Standard Deviation 3.4627	-1.632 femtolitres (fL) Standard Deviation 3.4207	-1.117 femtolitres (fL) Standard Deviation 3.4616	-2.171 femtolitres (fL) Standard Deviation 4.4367	-2.186 femtolitres (fL) Standard Deviation 3.4915

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Erythrocytes was measured in number of red blood cells per liter (10\^12/L).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 1	-0.148 10^12 red blood cells per liter Standard Deviation 0.2071	-0.008 10^12 red blood cells per liter Standard Deviation 0.1927	0.050 10^12 red blood cells per liter Standard Deviation 0.1773	0.008 10^12 red blood cells per liter Standard Deviation 0.2109	-0.017 10^12 red blood cells per liter Standard Deviation 0.1609
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 4	-0.132 10^12 red blood cells per liter Standard Deviation 0.2780	0.018 10^12 red blood cells per liter Standard Deviation 0.2535	0.023 10^12 red blood cells per liter Standard Deviation 0.2135	0.013 10^12 red blood cells per liter Standard Deviation 0.1955	0.031 10^12 red blood cells per liter Standard Deviation 0.2065
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 8	-0.135 10^12 red blood cells per liter Standard Deviation 0.2546	-0.011 10^12 red blood cells per liter Standard Deviation 0.2206	0.074 10^12 red blood cells per liter Standard Deviation 0.2466	0.014 10^12 red blood cells per liter Standard Deviation 0.2190	0.026 10^12 red blood cells per liter Standard Deviation 0.2264
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 12	-0.131 10^12 red blood cells per liter Standard Deviation 0.2678	0.021 10^12 red blood cells per liter Standard Deviation 0.2561	0.069 10^12 red blood cells per liter Standard Deviation 0.2419	0.051 10^12 red blood cells per liter Standard Deviation 0.2243	0.075 10^12 red blood cells per liter Standard Deviation 0.2393
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 16	-0.020 10^12 red blood cells per liter Standard Deviation 0.2375	0.075 10^12 red blood cells per liter Standard Deviation 0.2898	0.047 10^12 red blood cells per liter Standard Deviation 0.2810	0.074 10^12 red blood cells per liter Standard Deviation 0.2255	0.110 10^12 red blood cells per liter Standard Deviation 0.2533
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 32	-0.010 10^12 red blood cells per liter Standard Deviation 0.2461	0.104 10^12 red blood cells per liter Standard Deviation 0.2660	0.133 10^12 red blood cells per liter Standard Deviation 0.2716	0.061 10^12 red blood cells per liter Standard Deviation 0.2555	0.156 10^12 red blood cells per liter Standard Deviation 0.2714
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 36	0.044 10^12 red blood cells per liter Standard Deviation 0.2524	0.166 10^12 red blood cells per liter Standard Deviation 0.2542	0.156 10^12 red blood cells per liter Standard Deviation 0.2849	0.161 10^12 red blood cells per liter Standard Deviation 0.2399	0.145 10^12 red blood cells per liter Standard Deviation 0.2377
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 40	0.079 10^12 red blood cells per liter Standard Deviation 0.2682	0.177 10^12 red blood cells per liter Standard Deviation 0.2733	0.163 10^12 red blood cells per liter Standard Deviation 0.2736	0.141 10^12 red blood cells per liter Standard Deviation 0.2535	0.129 10^12 red blood cells per liter Standard Deviation 0.2403
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 44	0.035 10^12 red blood cells per liter Standard Deviation 0.2645	0.146 10^12 red blood cells per liter Standard Deviation 0.2846	0.133 10^12 red blood cells per liter Standard Deviation 0.2622	0.188 10^12 red blood cells per liter Standard Deviation 0.2933	0.135 10^12 red blood cells per liter Standard Deviation 0.2128
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 48	0.061 10^12 red blood cells per liter Standard Deviation 0.2693	0.146 10^12 red blood cells per liter Standard Deviation 0.2994	0.141 10^12 red blood cells per liter Standard Deviation 0.2747	0.135 10^12 red blood cells per liter Standard Deviation 0.2934	0.129 10^12 red blood cells per liter Standard Deviation 0.2354
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 2	-0.149 10^12 red blood cells per liter Standard Deviation 0.2244	-0.029 10^12 red blood cells per liter Standard Deviation 0.1788	-0.004 10^12 red blood cells per liter Standard Deviation 0.2280	-0.063 10^12 red blood cells per liter Standard Deviation 0.2236	0.000 10^12 red blood cells per liter Standard Deviation 0.1809
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 20	0.036 10^12 red blood cells per liter Standard Deviation 0.2618	0.096 10^12 red blood cells per liter Standard Deviation 0.2855	0.068 10^12 red blood cells per liter Standard Deviation 0.2089	0.064 10^12 red blood cells per liter Standard Deviation 0.2273	0.081 10^12 red blood cells per liter Standard Deviation 0.2191
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 24	0.059 10^12 red blood cells per liter Standard Deviation 0.2639	0.110 10^12 red blood cells per liter Standard Deviation 0.2974	0.142 10^12 red blood cells per liter Standard Deviation 0.2573	0.074 10^12 red blood cells per liter Standard Deviation 0.2250	0.110 10^12 red blood cells per liter Standard Deviation 0.1931
Changes From Baseline in Hematology Parameters During the Study (Erythrocytes) Week 28	-0.034 10^12 red blood cells per liter Standard Deviation 0.2453	0.108 10^12 red blood cells per liter Standard Deviation 0.2681	0.122 10^12 red blood cells per liter Standard Deviation 0.2445	0.058 10^12 red blood cells per liter Standard Deviation 0.2359	0.106 10^12 red blood cells per liter Standard Deviation 0.2567

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Hematocrit was measured in volume percentage (%) of red blood cells in blood.

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 1	-0.011 volume % of red blood cells Standard Deviation 0.0189	-0.001 volume % of red blood cells Standard Deviation 0.0211	0.007 volume % of red blood cells Standard Deviation 0.0181	0.000 volume % of red blood cells Standard Deviation 0.0206	-0.004 volume % of red blood cells Standard Deviation 0.0206
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 2	-0.011 volume % of red blood cells Standard Deviation 0.0230	-0.004 volume % of red blood cells Standard Deviation 0.0204	-0.000 volume % of red blood cells Standard Deviation 0.0205	-0.006 volume % of red blood cells Standard Deviation 0.0220	-0.003 volume % of red blood cells Standard Deviation 0.0174
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 12	-0.005 volume % of red blood cells Standard Deviation 0.0287	0.007 volume % of red blood cells Standard Deviation 0.0281	0.013 volume % of red blood cells Standard Deviation 0.0276	0.006 volume % of red blood cells Standard Deviation 0.0219	0.005 volume % of red blood cells Standard Deviation 0.0231
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 28	-0.007 volume % of red blood cells Standard Deviation 0.0210	0.004 volume % of red blood cells Standard Deviation 0.0248	0.008 volume % of red blood cells Standard Deviation 0.0241	-0.003 volume % of red blood cells Standard Deviation 0.0229	0.002 volume % of red blood cells Standard Deviation 0.0238
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 32	-0.009 volume % of red blood cells Standard Deviation 0.0207	0.000 volume % of red blood cells Standard Deviation 0.0249	0.007 volume % of red blood cells Standard Deviation 0.0225	-0.004 volume % of red blood cells Standard Deviation 0.0196	0.003 volume % of red blood cells Standard Deviation 0.0248
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 36	-0.004 volume % of red blood cells Standard Deviation 0.0222	0.004 volume % of red blood cells Standard Deviation 0.0228	0.009 volume % of red blood cells Standard Deviation 0.0258	0.003 volume % of red blood cells Standard Deviation 0.0221	0.003 volume % of red blood cells Standard Deviation 0.0234
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 4	-0.008 volume % of red blood cells Standard Deviation 0.0254	0.001 volume % of red blood cells Standard Deviation 0.0211	0.006 volume % of red blood cells Standard Deviation 0.0220	0.003 volume % of red blood cells Standard Deviation 0.0190	0.001 volume % of red blood cells Standard Deviation 0.0209
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 8	-0.007 volume % of red blood cells Standard Deviation 0.0239	0.003 volume % of red blood cells Standard Deviation 0.0244	0.012 volume % of red blood cells Standard Deviation 0.0237	0.005 volume % of red blood cells Standard Deviation 0.0208	0.003 volume % of red blood cells Standard Deviation 0.0232
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 16	0.004 volume % of red blood cells Standard Deviation 0.0202	0.012 volume % of red blood cells Standard Deviation 0.0259	0.011 volume % of red blood cells Standard Deviation 0.0254	0.006 volume % of red blood cells Standard Deviation 0.0240	0.010 volume % of red blood cells Standard Deviation 0.0252
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 20	0.006 volume % of red blood cells Standard Deviation 0.0217	0.007 volume % of red blood cells Standard Deviation 0.0270	0.010 volume % of red blood cells Standard Deviation 0.0211	0.004 volume % of red blood cells Standard Deviation 0.0241	0.008 volume % of red blood cells Standard Deviation 0.0246
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 24	0.001 volume % of red blood cells Standard Deviation 0.0192	0.006 volume % of red blood cells Standard Deviation 0.0253	0.014 volume % of red blood cells Standard Deviation 0.0256	-0.000 volume % of red blood cells Standard Deviation 0.0222	0.005 volume % of red blood cells Standard Deviation 0.0219
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 40	0.000 volume % of red blood cells Standard Deviation 0.0231	0.007 volume % of red blood cells Standard Deviation 0.0278	0.007 volume % of red blood cells Standard Deviation 0.0246	-0.001 volume % of red blood cells Standard Deviation 0.0221	0.000 volume % of red blood cells Standard Deviation 0.0206
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 44	-0.003 volume % of red blood cells Standard Deviation 0.0272	0.006 volume % of red blood cells Standard Deviation 0.0297	0.007 volume % of red blood cells Standard Deviation 0.0239	0.007 volume % of red blood cells Standard Deviation 0.0246	0.002 volume % of red blood cells Standard Deviation 0.0194
Changes From Baseline in Hematology Parameters During the Study (Hematocrit) Week 48	0.001 volume % of red blood cells Standard Deviation 0.0243	0.007 volume % of red blood cells Standard Deviation 0.0257	0.009 volume % of red blood cells Standard Deviation 0.0260	0.005 volume % of red blood cells Standard Deviation 0.0252	0.004 volume % of red blood cells Standard Deviation 0.0212

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Platelets was measured in number of platelets per liter (10\^9/L).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 1	-5.073 10^9 platelets per liter Standard Deviation 30.2609	-3.368 10^9 platelets per liter Standard Deviation 25.9515	3.209 10^9 platelets per liter Standard Deviation 30.5883	-2.098 10^9 platelets per liter Standard Deviation 24.6412	-9.325 10^9 platelets per liter Standard Deviation 23.4109
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 2	4.000 10^9 platelets per liter Standard Deviation 27.3112	-5.179 10^9 platelets per liter Standard Deviation 38.2800	-3.810 10^9 platelets per liter Standard Deviation 41.8250	-15.122 10^9 platelets per liter Standard Deviation 32.8414	-15.415 10^9 platelets per liter Standard Deviation 31.7025
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 4	-3.927 10^9 platelets per liter Standard Deviation 29.6643	-6.868 10^9 platelets per liter Standard Deviation 29.7487	-13.878 10^9 platelets per liter Standard Deviation 43.7568	-19.415 10^9 platelets per liter Standard Deviation 32.6450	-27.073 10^9 platelets per liter Standard Deviation 41.9299
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 8	1.561 10^9 platelets per liter Standard Deviation 29.1042	-12.077 10^9 platelets per liter Standard Deviation 28.9876	-5.475 10^9 platelets per liter Standard Deviation 44.7718	-17.605 10^9 platelets per liter Standard Deviation 29.8442	-26.195 10^9 platelets per liter Standard Deviation 44.1719
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 12	-2.171 10^9 platelets per liter Standard Deviation 32.0795	-17.359 10^9 platelets per liter Standard Deviation 35.4308	-11.286 10^9 platelets per liter Standard Deviation 40.7451	-10.079 10^9 platelets per liter Standard Deviation 44.8977	-23.171 10^9 platelets per liter Standard Deviation 47.2995
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 16	-18.833 10^9 platelets per liter Standard Deviation 50.4844	-18.263 10^9 platelets per liter Standard Deviation 37.3259	-13.952 10^9 platelets per liter Standard Deviation 50.7173	-9.895 10^9 platelets per liter Standard Deviation 35.3246	-25.425 10^9 platelets per liter Standard Deviation 37.6556
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 20	-18.625 10^9 platelets per liter Standard Deviation 50.3988	-23.077 10^9 platelets per liter Standard Deviation 39.6534	-10.512 10^9 platelets per liter Standard Deviation 48.0755	-15.324 10^9 platelets per liter Standard Deviation 28.8329	-22.725 10^9 platelets per liter Standard Deviation 42.2502
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 24	-19.974 10^9 platelets per liter Standard Deviation 49.0196	-14.000 10^9 platelets per liter Standard Deviation 37.7760	-4.600 10^9 platelets per liter Standard Deviation 49.4025	-10.972 10^9 platelets per liter Standard Deviation 36.8375	-22.900 10^9 platelets per liter Standard Deviation 47.4092
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 28	-24.256 10^9 platelets per liter Standard Deviation 51.8001	-16.868 10^9 platelets per liter Standard Deviation 40.6635	-7.683 10^9 platelets per liter Standard Deviation 47.8155	-12.800 10^9 platelets per liter Standard Deviation 30.7904	-19.600 10^9 platelets per liter Standard Deviation 42.3052
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 32	-22.410 10^9 platelets per liter Standard Deviation 51.9553	-18.590 10^9 platelets per liter Standard Deviation 41.7226	-13.575 10^9 platelets per liter Standard Deviation 51.9304	-20.618 10^9 platelets per liter Standard Deviation 38.8969	-23.179 10^9 platelets per liter Standard Deviation 42.2018
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 36	-25.000 10^9 platelets per liter Standard Deviation 52.6990	-16.474 10^9 platelets per liter Standard Deviation 46.8844	-14.561 10^9 platelets per liter Standard Deviation 50.2106	-18.848 10^9 platelets per liter Standard Deviation 40.0563	-23.846 10^9 platelets per liter Standard Deviation 45.1340
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 40	-23.432 10^9 platelets per liter Standard Deviation 53.2747	-20.895 10^9 platelets per liter Standard Deviation 41.4845	-14.927 10^9 platelets per liter Standard Deviation 51.2652	-24.088 10^9 platelets per liter Standard Deviation 33.4133	-21.789 10^9 platelets per liter Standard Deviation 46.1467
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 44	-22.703 10^9 platelets per liter Standard Deviation 57.8383	-22.474 10^9 platelets per liter Standard Deviation 41.0627	-18.051 10^9 platelets per liter Standard Deviation 49.1646	-24.735 10^9 platelets per liter Standard Deviation 38.4710	-31.389 10^9 platelets per liter Standard Deviation 48.5306
Changes From Baseline in Hematology Parameters During the Study (Platelets) Week 48	-27.395 10^9 platelets per liter Standard Deviation 56.2963	-23.811 10^9 platelets per liter Standard Deviation 47.1150	-24.220 10^9 platelets per liter Standard Deviation 46.2458	-22.273 10^9 platelets per liter Standard Deviation 37.4243	-28.974 10^9 platelets per liter Standard Deviation 42.9960

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase were measured in units per liter (U/L).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 2	-1.714 U/L Standard Deviation 15.4624	2.026 U/L Standard Deviation 8.9428	-1.047 U/L Standard Deviation 41.1223	4.927 U/L Standard Deviation 20.9623	1.171 U/L Standard Deviation 10.2978
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 8	-4.707 U/L Standard Deviation 13.6478	-1.385 U/L Standard Deviation 9.4580	5.465 U/L Standard Deviation 68.0764	0.795 U/L Standard Deviation 11.4321	-1.659 U/L Standard Deviation 11.1009
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 16	-2.048 U/L Standard Deviation 18.0026	2.684 U/L Standard Deviation 16.3229	-4.857 U/L Standard Deviation 38.6211	0.579 U/L Standard Deviation 12.9273	0.829 U/L Standard Deviation 11.5432
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 20	0.300 U/L Standard Deviation 39.9482	3.821 U/L Standard Deviation 13.0139	-4.881 U/L Standard Deviation 39.1808	-0.838 U/L Standard Deviation 11.1118	-1.350 U/L Standard Deviation 10.5479
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 1	-1.098 U/L Standard Deviation 6.0034	-1.342 U/L Standard Deviation 8.0983	-2.721 U/L Standard Deviation 7.2056	-3.244 U/L Standard Deviation 4.9989	-4.275 U/L Standard Deviation 7.1360
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 4	-1.634 U/L Standard Deviation 9.0630	-1.077 U/L Standard Deviation 10.4236	-3.262 U/L Standard Deviation 9.9144	-1.439 U/L Standard Deviation 18.3508	-4.829 U/L Standard Deviation 10.9268
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 8	-2.220 U/L Standard Deviation 8.3711	0.308 U/L Standard Deviation 12.6515	1.233 U/L Standard Deviation 37.8014	-5.026 U/L Standard Deviation 10.2019	-3.585 U/L Standard Deviation 9.8336
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 12	-2.463 U/L Standard Deviation 8.8122	-0.462 U/L Standard Deviation 12.1066	-5.952 U/L Standard Deviation 11.0695	-4.947 U/L Standard Deviation 12.0538	-3.146 U/L Standard Deviation 17.2476
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 16	-8.357 U/L Standard Deviation 12.7276	-0.895 U/L Standard Deviation 13.1515	-7.238 U/L Standard Deviation 10.7722	-4.605 U/L Standard Deviation 11.6539	-1.512 U/L Standard Deviation 25.7722
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 36	-11.816 U/L Standard Deviation 19.2436	-6.368 U/L Standard Deviation 15.4735	-11.122 U/L Standard Deviation 12.3495	-8.059 U/L Standard Deviation 9.5217	-6.487 U/L Standard Deviation 19.2434
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 48	-12.211 U/L Standard Deviation 19.0379	-6.500 U/L Standard Deviation 16.5313	-11.049 U/L Standard Deviation 14.4827	-7.765 U/L Standard Deviation 12.3290	-7.875 U/L Standard Deviation 20.1370
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 1	-2.854 U/L Standard Deviation 10.3212	1.447 U/L Standard Deviation 6.2155	-0.023 U/L Standard Deviation 27.5409	2.244 U/L Standard Deviation 6.7889	0.475 U/L Standard Deviation 5.2963
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 4	-3.976 U/L Standard Deviation 10.6642	1.289 U/L Standard Deviation 7.5584	-3.262 U/L Standard Deviation 25.1047	8.927 U/L Standard Deviation 52.0660	-1.195 U/L Standard Deviation 4.2791
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 8	-1.829 U/L Standard Deviation 5.9745	-4.410 U/L Standard Deviation 11.6319	11.581 U/L Standard Deviation 103.8974	-1.795 U/L Standard Deviation 5.7454	-1.805 U/L Standard Deviation 9.0698
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 12	-0.927 U/L Standard Deviation 28.3058	4.077 U/L Standard Deviation 21.0905	2.119 U/L Standard Deviation 27.5134	3.342 U/L Standard Deviation 17.0346	1.049 U/L Standard Deviation 22.9303
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 24	-1.564 U/L Standard Deviation 19.4974	2.789 U/L Standard Deviation 14.5475	-5.659 U/L Standard Deviation 39.6652	1.528 U/L Standard Deviation 11.0259	-3.475 U/L Standard Deviation 8.6202
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 28	-3.385 U/L Standard Deviation 17.7373	2.658 U/L Standard Deviation 12.8174	-3.244 U/L Standard Deviation 43.4688	-0.171 U/L Standard Deviation 8.7228	-2.775 U/L Standard Deviation 10.4280
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 32	-4.487 U/L Standard Deviation 16.5400	2.385 U/L Standard Deviation 12.8956	-4.150 U/L Standard Deviation 44.0126	-2.176 U/L Standard Deviation 12.7742	-0.821 U/L Standard Deviation 11.5482
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 36	0.579 U/L Standard Deviation 10.5411	0.184 U/L Standard Deviation 11.8660	-2.976 U/L Standard Deviation 42.9275	-0.471 U/L Standard Deviation 11.2848	-1.103 U/L Standard Deviation 10.6296
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 40	-0.622 U/L Standard Deviation 10.2506	0.816 U/L Standard Deviation 12.6680	-2.780 U/L Standard Deviation 44.9719	-3.853 U/L Standard Deviation 11.1059	-1.385 U/L Standard Deviation 13.1061
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 44	2.649 U/L Standard Deviation 19.7993	1.474 U/L Standard Deviation 13.1514	-3.415 U/L Standard Deviation 43.2966	-3.882 U/L Standard Deviation 12.8741	-2.692 U/L Standard Deviation 10.2525
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 48	2.605 U/L Standard Deviation 14.0646	2.216 U/L Standard Deviation 12.8542	-4.561 U/L Standard Deviation 43.1926	-3.794 U/L Standard Deviation 13.1628	-0.575 U/L Standard Deviation 9.6181
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 2	-1.905 U/L Standard Deviation 6.7960	-3.282 U/L Standard Deviation 7.8370	-4.349 U/L Standard Deviation 9.5963	-4.805 U/L Standard Deviation 7.8237	-3.585 U/L Standard Deviation 8.8430
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 20	-10.425 U/L Standard Deviation 14.0510	-5.410 U/L Standard Deviation 15.1895	-10.143 U/L Standard Deviation 13.0264	-7.027 U/L Standard Deviation 11.8544	-6.650 U/L Standard Deviation 14.8143
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 24	-12.795 U/L Standard Deviation 15.4752	-4.769 U/L Standard Deviation 13.8097	-9.463 U/L Standard Deviation 11.3448	-6.361 U/L Standard Deviation 12.7843	-7.225 U/L Standard Deviation 18.4231
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 28	-12.795 U/L Standard Deviation 16.9351	-5.684 U/L Standard Deviation 15.7259	-11.244 U/L Standard Deviation 12.6249	-8.314 U/L Standard Deviation 10.9054	-8.525 U/L Standard Deviation 16.8523
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 32	-13.667 U/L Standard Deviation 16.1870	-4.769 U/L Standard Deviation 16.1530	-10.900 U/L Standard Deviation 13.0026	-9.118 U/L Standard Deviation 12.5765	-8.385 U/L Standard Deviation 17.5988
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 40	-11.000 U/L Standard Deviation 16.9706	-5.658 U/L Standard Deviation 15.7485	-11.024 U/L Standard Deviation 12.9180	-10.559 U/L Standard Deviation 11.6987	-8.175 U/L Standard Deviation 17.8884
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alkaline Phosphatase Week 44	-12.622 U/L Standard Deviation 17.6373	-6.421 U/L Standard Deviation 14.9099	-10.537 U/L Standard Deviation 13.5759	-8.647 U/L Standard Deviation 10.5483	-8.950 U/L Standard Deviation 18.3162
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 2	-1.762 U/L Standard Deviation 10.5294	0.487 U/L Standard Deviation 4.0967	-2.233 U/L Standard Deviation 26.3266	3.805 U/L Standard Deviation 14.7635	0.780 U/L Standard Deviation 6.1746
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 8	-3.537 U/L Standard Deviation 10.5477	-0.077 U/L Standard Deviation 5.8687	2.279 U/L Standard Deviation 34.7805	1.410 U/L Standard Deviation 5.5900	0.366 U/L Standard Deviation 6.1877
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 12	-3.049 U/L Standard Deviation 12.2106	0.436 U/L Standard Deviation 5.3054	-2.595 U/L Standard Deviation 22.5324	1.053 U/L Standard Deviation 6.9006	1.122 U/L Standard Deviation 6.2897
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 16	-1.048 U/L Standard Deviation 12.1313	2.974 U/L Standard Deviation 8.3649	-2.595 U/L Standard Deviation 24.3852	1.526 U/L Standard Deviation 6.6688	2.122 U/L Standard Deviation 6.1733
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 20	6.375 U/L Standard Deviation 60.1309	2.821 U/L Standard Deviation 6.6367	-1.095 U/L Standard Deviation 25.1317	1.324 U/L Standard Deviation 7.1065	0.500 U/L Standard Deviation 4.8569
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 24	1.718 U/L Standard Deviation 23.7940	2.237 U/L Standard Deviation 6.9182	-1.902 U/L Standard Deviation 26.1054	2.889 U/L Standard Deviation 6.2554	0.325 U/L Standard Deviation 4.3759
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 28	-1.179 U/L Standard Deviation 13.4905	2.289 U/L Standard Deviation 6.9512	-1.805 U/L Standard Deviation 27.4583	2.229 U/L Standard Deviation 6.3063	0.175 U/L Standard Deviation 4.1255
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 32	-1.385 U/L Standard Deviation 12.2895	1.949 U/L Standard Deviation 6.2826	-0.575 U/L Standard Deviation 28.3177	0.324 U/L Standard Deviation 6.2654	2.051 U/L Standard Deviation 4.9997
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 36	0.711 U/L Standard Deviation 7.3113	1.026 U/L Standard Deviation 5.5140	-1.220 U/L Standard Deviation 25.5798	1.588 U/L Standard Deviation 6.6017	1.667 U/L Standard Deviation 6.0755
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 40	0.946 U/L Standard Deviation 12.1494	1.316 U/L Standard Deviation 5.5269	0.244 U/L Standard Deviation 29.2701	-0.647 U/L Standard Deviation 6.0597	2.462 U/L Standard Deviation 8.4972
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 44	2.838 U/L Standard Deviation 15.4641	2.553 U/L Standard Deviation 7.9175	-1.268 U/L Standard Deviation 28.4280	-0.588 U/L Standard Deviation 7.7190	1.590 U/L Standard Deviation 6.9347
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Aspartate Aminotransferase Week 48	2.158 U/L Standard Deviation 9.7939	3.459 U/L Standard Deviation 6.3403	-1.927 U/L Standard Deviation 28.3182	0.441 U/L Standard Deviation 6.6796	2.900 U/L Standard Deviation 6.2339
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 1	0.171 U/L Standard Deviation 5.4447	-2.737 U/L Standard Deviation 7.0354	-0.535 U/L Standard Deviation 10.8745	0.171 U/L Standard Deviation 5.0245	-2.300 U/L Standard Deviation 6.2684
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 2	-0.190 U/L Standard Deviation 5.8736	-2.026 U/L Standard Deviation 7.6828	-4.116 U/L Standard Deviation 25.7527	-0.341 U/L Standard Deviation 5.2517	-1.268 U/L Standard Deviation 7.8773
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 4	-0.220 U/L Standard Deviation 7.2129	-2.641 U/L Standard Deviation 9.9167	-6.143 U/L Standard Deviation 35.5504	1.171 U/L Standard Deviation 17.6265	0.512 U/L Standard Deviation 16.3968
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 12	-0.585 U/L Standard Deviation 5.9033	-2.154 U/L Standard Deviation 10.7643	-5.762 U/L Standard Deviation 34.8767	-0.447 U/L Standard Deviation 8.3785	3.244 U/L Standard Deviation 21.8229
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 16	-0.357 U/L Standard Deviation 9.6445	-1.842 U/L Standard Deviation 13.4476	-4.357 U/L Standard Deviation 34.0020	-0.947 U/L Standard Deviation 8.1868	15.024 U/L Standard Deviation 77.1617
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 20	-0.750 U/L Standard Deviation 9.5051	-2.769 U/L Standard Deviation 13.0555	-5.452 U/L Standard Deviation 32.1970	-1.649 U/L Standard Deviation 5.5137	1.475 U/L Standard Deviation 22.2722
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 24	-0.615 U/L Standard Deviation 12.4173	-2.769 U/L Standard Deviation 10.9339	-4.122 U/L Standard Deviation 36.6832	-2.639 U/L Standard Deviation 9.4360	-2.625 U/L Standard Deviation 10.3272
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 28	-0.462 U/L Standard Deviation 11.5618	-2.132 U/L Standard Deviation 11.7638	-6.341 U/L Standard Deviation 36.7434	-2.629 U/L Standard Deviation 7.6354	-0.200 U/L Standard Deviation 11.5585
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 32	0.359 U/L Standard Deviation 15.7872	-1.538 U/L Standard Deviation 13.2463	-7.875 U/L Standard Deviation 36.9103	-3.676 U/L Standard Deviation 8.6435	2.795 U/L Standard Deviation 21.1501
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 36	-0.026 U/L Standard Deviation 14.7162	-4.289 U/L Standard Deviation 11.4559	-8.195 U/L Standard Deviation 38.6899	-2.735 U/L Standard Deviation 7.1236	1.410 U/L Standard Deviation 18.0200
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 40	-2.568 U/L Standard Deviation 9.3676	-3.842 U/L Standard Deviation 13.9275	-9.073 U/L Standard Deviation 40.5792	-4.088 U/L Standard Deviation 7.5573	0.925 U/L Standard Deviation 20.1066
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 44	1.081 U/L Standard Deviation 23.2108	-1.289 U/L Standard Deviation 21.3730	-7.488 U/L Standard Deviation 34.4145	-3.824 U/L Standard Deviation 7.0430	-0.949 U/L Standard Deviation 11.5643
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Gamma Glutamyl Transferase Week 48	1.474 U/L Standard Deviation 17.6723	-2.184 U/L Standard Deviation 12.0850	-7.805 U/L Standard Deviation 35.4924	-2.941 U/L Standard Deviation 8.8247	2.525 U/L Standard Deviation 20.6112
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 1	-7.000 U/L Standard Deviation 16.1509	0.026 U/L Standard Deviation 19.6118	-1.163 U/L Standard Deviation 33.1669	-0.585 U/L Standard Deviation 16.6673	-1.075 U/L Standard Deviation 18.4341
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 2	-5.929 U/L Standard Deviation 18.4858	-0.410 U/L Standard Deviation 14.9045	-5.930 U/L Standard Deviation 32.8325	-2.439 U/L Standard Deviation 19.2146	0.537 U/L Standard Deviation 19.7270
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 4	-5.634 U/L Standard Deviation 25.5693	4.846 U/L Standard Deviation 21.4372	-6.190 U/L Standard Deviation 29.5265	0.854 U/L Standard Deviation 26.6238	-4.293 U/L Standard Deviation 17.4732
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 8	-3.561 U/L Standard Deviation 17.3249	0.026 U/L Standard Deviation 19.0449	0.140 U/L Standard Deviation 38.8413	3.513 U/L Standard Deviation 18.6503	1.439 U/L Standard Deviation 24.0230
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 16	0.881 U/L Standard Deviation 26.0180	15.447 U/L Standard Deviation 62.0267	-4.381 U/L Standard Deviation 35.9600	0.474 U/L Standard Deviation 19.8967	1.488 U/L Standard Deviation 21.8325
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 20	1.200 U/L Standard Deviation 35.1817	2.154 U/L Standard Deviation 22.8825	2.500 U/L Standard Deviation 31.6145	0.676 U/L Standard Deviation 20.9206	2.025 U/L Standard Deviation 23.0401
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 24	4.462 U/L Standard Deviation 31.9282	1.333 U/L Standard Deviation 22.1862	2.878 U/L Standard Deviation 44.9662	1.944 U/L Standard Deviation 23.5638	8.550 U/L Standard Deviation 25.3093
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 28	1.436 U/L Standard Deviation 21.1122	-4.763 U/L Standard Deviation 21.2138	-2.902 U/L Standard Deviation 34.3590	8.143 U/L Standard Deviation 44.0929	1.250 U/L Standard Deviation 22.0962
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 32	-6.333 U/L Standard Deviation 23.0587	-6.410 U/L Standard Deviation 23.8324	-4.525 U/L Standard Deviation 35.2762	-2.971 U/L Standard Deviation 27.9171	-1.615 U/L Standard Deviation 24.8052
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 36	0.553 U/L Standard Deviation 37.3889	-4.658 U/L Standard Deviation 16.8383	-7.585 U/L Standard Deviation 35.0442	-6.147 U/L Standard Deviation 21.6895	5.436 U/L Standard Deviation 30.0436
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 40	-0.216 U/L Standard Deviation 34.5214	-8.289 U/L Standard Deviation 17.4896	-6.366 U/L Standard Deviation 36.6898	-10.618 U/L Standard Deviation 24.4293	0.000 U/L Standard Deviation 29.3852
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 44	-0.757 U/L Standard Deviation 32.2847	-5.316 U/L Standard Deviation 21.4805	-5.000 U/L Standard Deviation 34.6259	-5.059 U/L Standard Deviation 22.2683	1.675 U/L Standard Deviation 24.9588
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Lactate Dehydrogenase Week 48	4.447 U/L Standard Deviation 34.3493	-1.395 U/L Standard Deviation 23.8061	-4.707 U/L Standard Deviation 38.6654	-7.441 U/L Standard Deviation 23.0443	4.500 U/L Standard Deviation 37.8120
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 1	-1.366 U/L Standard Deviation 12.7451	2.526 U/L Standard Deviation 15.5211	2.628 U/L Standard Deviation 42.1234	3.122 U/L Standard Deviation 10.2791	0.700 U/L Standard Deviation 9.5868
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 4	-3.854 U/L Standard Deviation 15.1897	1.553 U/L Standard Deviation 16.2758	-3.952 U/L Standard Deviation 38.9546	22.756 U/L Standard Deviation 139.8531	-1.561 U/L Standard Deviation 10.1392
Changes From Baseline in Biochemistry Parameters During the Study (Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase, Lactate Dehydrogenase) Alanine Aminotransferase Week 12	-4.220 U/L Standard Deviation 15.1765	0.359 U/L Standard Deviation 12.2356	-4.429 U/L Standard Deviation 38.1756	1.184 U/L Standard Deviation 13.0692	-1.390 U/L Standard Deviation 8.1941

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Albumin was measured in grams per liter (g/L).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 24	0.385 g/L Standard Deviation 1.7262	0.949 g/L Standard Deviation 2.3164	1.341 g/L Standard Deviation 1.8790	0.722 g/L Standard Deviation 2.2502	0.875 g/L Standard Deviation 2.3004
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 1	-1.000 g/L Standard Deviation 1.7464	-0.079 g/L Standard Deviation 2.1357	0.279 g/L Standard Deviation 1.8038	-0.439 g/L Standard Deviation 1.8715	-0.350 g/L Standard Deviation 1.6259
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 2	-0.500 g/L Standard Deviation 2.0982	0.051 g/L Standard Deviation 1.5719	0.419 g/L Standard Deviation 1.9908	-0.537 g/L Standard Deviation 2.0988	-0.073 g/L Standard Deviation 1.8220
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 4	-0.683 g/L Standard Deviation 2.4743	0.538 g/L Standard Deviation 2.1007	0.595 g/L Standard Deviation 1.9514	-0.171 g/L Standard Deviation 1.9862	0.220 g/L Standard Deviation 1.9687
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 8	-0.634 g/L Standard Deviation 2.0094	0.154 g/L Standard Deviation 2.1829	0.581 g/L Standard Deviation 2.0843	0.077 g/L Standard Deviation 2.2051	0.195 g/L Standard Deviation 1.7638
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 12	0.073 g/L Standard Deviation 2.4020	0.538 g/L Standard Deviation 2.1986	0.857 g/L Standard Deviation 1.8685	0.211 g/L Standard Deviation 1.9474	0.415 g/L Standard Deviation 2.1210
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 16	0.833 g/L Standard Deviation 1.8468	1.132 g/L Standard Deviation 2.2800	0.881 g/L Standard Deviation 2.0025	0.316 g/L Standard Deviation 2.0678	0.683 g/L Standard Deviation 1.9422
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 20	0.175 g/L Standard Deviation 1.9333	0.487 g/L Standard Deviation 2.4047	0.976 g/L Standard Deviation 1.7873	-0.081 g/L Standard Deviation 2.1000	0.575 g/L Standard Deviation 1.8659
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 28	-0.462 g/L Standard Deviation 2.0881	0.632 g/L Standard Deviation 2.1362	0.976 g/L Standard Deviation 1.9169	0.114 g/L Standard Deviation 1.9819	0.525 g/L Standard Deviation 2.0999
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 32	-0.179 g/L Standard Deviation 1.7452	0.359 g/L Standard Deviation 1.8706	0.700 g/L Standard Deviation 1.9897	-0.235 g/L Standard Deviation 1.6341	0.667 g/L Standard Deviation 1.9912
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 36	-0.289 g/L Standard Deviation 2.6397	0.816 g/L Standard Deviation 1.7220	0.659 g/L Standard Deviation 1.6064	-0.029 g/L Standard Deviation 2.0815	0.436 g/L Standard Deviation 1.9166
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 40	-0.108 g/L Standard Deviation 2.0109	0.763 g/L Standard Deviation 1.9650	0.805 g/L Standard Deviation 1.8196	0.000 g/L Standard Deviation 1.8749	0.400 g/L Standard Deviation 1.9716
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 44	-0.297 g/L Standard Deviation 2.0120	0.132 g/L Standard Deviation 2.3269	0.659 g/L Standard Deviation 2.2429	-0.206 g/L Standard Deviation 1.9661	0.175 g/L Standard Deviation 2.2858
Changes From Baseline in Biochemistry Parameters During the Study (Albumin) Week 48	0.132 g/L Standard Deviation 2.2800	0.632 g/L Standard Deviation 2.9903	0.366 g/L Standard Deviation 3.1682	0.088 g/L Standard Deviation 2.6671	0.150 g/L Standard Deviation 2.3044

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Bilirubin, creatinine, urate were measured in micromols per liter (μmol/L).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 1	-0.841 μmol/L Standard Deviation 2.8968	-1.195 μmol/L Standard Deviation 3.1083	-0.465 μmol/L Standard Deviation 3.4868	0.471 μmol/L Standard Deviation 3.0332	0.385 μmol/L Standard Deviation 2.2726
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 4	-0.290 μmol/L Standard Deviation 3.4900	0.789 μmol/L Standard Deviation 2.8952	-0.119 μmol/L Standard Deviation 3.2318	1.066 μmol/L Standard Deviation 3.4454	1.344 μmol/L Standard Deviation 3.7625
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 16	0.607 μmol/L Standard Deviation 3.7361	0.637 μmol/L Standard Deviation 3.7786	0.740 μmol/L Standard Deviation 3.2505	1.092 μmol/L Standard Deviation 3.7662	2.024 μmol/L Standard Deviation 3.7217
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 8	1.366 μmol/L Standard Deviation 8.3269	1.487 μmol/L Standard Deviation 8.3756	3.674 μmol/L Standard Deviation 10.1997	1.590 μmol/L Standard Deviation 7.9131	3.073 μmol/L Standard Deviation 5.7810
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 12	1.268 μmol/L Standard Deviation 8.0282	0.949 μmol/L Standard Deviation 8.6113	6.214 μmol/L Standard Deviation 9.5062	1.947 μmol/L Standard Deviation 9.1236	2.220 μmol/L Standard Deviation 8.2417
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 16	1.833 μmol/L Standard Deviation 8.4678	1.421 μmol/L Standard Deviation 10.7945	3.738 μmol/L Standard Deviation 7.7964	0.658 μmol/L Standard Deviation 8.7897	3.976 μmol/L Standard Deviation 8.2719
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 28	2.921 μmol/L Standard Deviation 7.0227	1.737 μmol/L Standard Deviation 7.4858	4.634 μmol/L Standard Deviation 8.9576	1.371 μmol/L Standard Deviation 8.3634	4.900 μmol/L Standard Deviation 7.2388
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 36	0.289 μmol/L Standard Deviation 7.5656	1.632 μmol/L Standard Deviation 7.1600	1.024 μmol/L Standard Deviation 8.8218	1.853 μmol/L Standard Deviation 10.8492	3.462 μmol/L Standard Deviation 6.8127
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 2	12.405 μmol/L Standard Deviation 47.5795	-2.974 μmol/L Standard Deviation 44.8826	9.791 μmol/L Standard Deviation 61.4009	9.073 μmol/L Standard Deviation 39.3430	15.610 μmol/L Standard Deviation 49.0693
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 28	-0.897 μmol/L Standard Deviation 29.4331	9.447 μmol/L Standard Deviation 59.8655	18.976 μmol/L Standard Deviation 62.4894	-6.371 μmol/L Standard Deviation 40.1227	1.250 μmol/L Standard Deviation 45.8972
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 2	-0.762 μmol/L Standard Deviation 2.9415	0.492 μmol/L Standard Deviation 3.1202	0.516 μmol/L Standard Deviation 2.7030	0.978 μmol/L Standard Deviation 2.9538	1.395 μmol/L Standard Deviation 4.0672
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 8	-0.776 μmol/L Standard Deviation 3.7242	0.541 μmol/L Standard Deviation 3.1822	0.442 μmol/L Standard Deviation 3.8005	0.972 μmol/L Standard Deviation 3.4557	0.639 μmol/L Standard Deviation 2.8243
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 12	-0.261 μmol/L Standard Deviation 2.6113	0.341 μmol/L Standard Deviation 3.0050	0.095 μmol/L Standard Deviation 2.5793	0.629 μmol/L Standard Deviation 3.2367	2.073 μmol/L Standard Deviation 4.0034
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 20	-0.007 μmol/L Standard Deviation 3.3543	0.136 μmol/L Standard Deviation 3.4239	1.062 μmol/L Standard Deviation 3.8164	1.030 μmol/L Standard Deviation 3.8636	1.225 μmol/L Standard Deviation 2.9632
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 24	0.146 μmol/L Standard Deviation 3.2508	0.592 μmol/L Standard Deviation 4.4981	0.383 μmol/L Standard Deviation 3.1235	1.081 μmol/L Standard Deviation 2.8708	1.128 μmol/L Standard Deviation 2.8112
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 28	-0.200 μmol/L Standard Deviation 3.6974	-0.068 μmol/L Standard Deviation 3.8885	0.105 μmol/L Standard Deviation 2.5550	0.449 μmol/L Standard Deviation 3.4106	1.595 μmol/L Standard Deviation 3.4093
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 32	0.233 μmol/L Standard Deviation 3.2668	0.262 μmol/L Standard Deviation 3.7358	0.655 μmol/L Standard Deviation 3.1125	0.994 μmol/L Standard Deviation 2.6879	1.669 μmol/L Standard Deviation 4.0868
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 36	0.942 μmol/L Standard Deviation 3.6870	0.776 μmol/L Standard Deviation 4.3703	0.078 μmol/L Standard Deviation 3.8443	1.012 μmol/L Standard Deviation 3.5311	1.095 μmol/L Standard Deviation 2.3971
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 40	0.600 μmol/L Standard Deviation 3.8064	0.679 μmol/L Standard Deviation 3.4707	0.415 μmol/L Standard Deviation 3.3481	1.065 μmol/L Standard Deviation 3.1718	1.433 μmol/L Standard Deviation 3.3425
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 44	-0.019 μmol/L Standard Deviation 3.6800	-0.276 μmol/L Standard Deviation 3.1827	-0.102 μmol/L Standard Deviation 3.1253	0.871 μmol/L Standard Deviation 2.8347	1.851 μmol/L Standard Deviation 3.7976
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Bilirubin Week 48	0.716 μmol/L Standard Deviation 4.0370	0.559 μmol/L Standard Deviation 3.2460	0.285 μmol/L Standard Deviation 3.8393	1.124 μmol/L Standard Deviation 3.2882	1.160 μmol/L Standard Deviation 3.9493
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 1	-0.512 μmol/L Standard Deviation 6.6788	0.368 μmol/L Standard Deviation 7.3757	2.442 μmol/L Standard Deviation 7.8628	1.366 μmol/L Standard Deviation 8.9044	1.300 μmol/L Standard Deviation 6.7300
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 2	2.310 μmol/L Standard Deviation 11.1300	0.026 μmol/L Standard Deviation 6.1194	2.093 μmol/L Standard Deviation 8.4426	2.537 μmol/L Standard Deviation 6.8304	3.317 μmol/L Standard Deviation 6.7470
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 4	0.854 μmol/L Standard Deviation 10.2508	1.256 μmol/L Standard Deviation 7.0812	1.762 μmol/L Standard Deviation 8.8229	-0.561 μmol/L Standard Deviation 7.3418	2.171 μmol/L Standard Deviation 6.9279
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 20	3.150 μmol/L Standard Deviation 8.3468	1.051 μmol/L Standard Deviation 7.7966	4.976 μmol/L Standard Deviation 10.5818	2.270 μmol/L Standard Deviation 8.5461	4.525 μmol/L Standard Deviation 7.4144
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 24	1.359 μmol/L Standard Deviation 8.1741	0.103 μmol/L Standard Deviation 6.8817	3.829 μmol/L Standard Deviation 11.4256	1.972 μmol/L Standard Deviation 9.3914	4.650 μmol/L Standard Deviation 7.2627
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 32	1.718 μmol/L Standard Deviation 8.8227	2.462 μmol/L Standard Deviation 9.1360	2.500 μmol/L Standard Deviation 8.9299	4.118 μmol/L Standard Deviation 12.0825	4.974 μmol/L Standard Deviation 7.7408
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 40	3.838 μmol/L Standard Deviation 9.5205	2.974 μmol/L Standard Deviation 7.3796	4.122 μmol/L Standard Deviation 9.7575	0.647 μmol/L Standard Deviation 10.7672	3.200 μmol/L Standard Deviation 7.0208
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 44	4.543 μmol/L Standard Deviation 10.6670	4.250 μmol/L Standard Deviation 8.7876	3.659 μmol/L Standard Deviation 8.5311	3.364 μmol/L Standard Deviation 10.6853	3.925 μmol/L Standard Deviation 8.0012
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Creatinine Week 48	3.000 μmol/L Standard Deviation 10.3299	4.667 μmol/L Standard Deviation 8.5355	3.923 μmol/L Standard Deviation 7.7371	2.879 μmol/L Standard Deviation 9.8513	3.256 μmol/L Standard Deviation 7.0290
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 1	-1.220 μmol/L Standard Deviation 37.4503	-0.237 μmol/L Standard Deviation 43.0100	11.953 μmol/L Standard Deviation 60.5652	8.732 μmol/L Standard Deviation 39.4088	11.650 μmol/L Standard Deviation 61.0924
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 4	10.171 μmol/L Standard Deviation 41.5493	0.308 μmol/L Standard Deviation 47.3193	13.452 μmol/L Standard Deviation 49.1633	5.659 μmol/L Standard Deviation 31.2591	-4.293 μmol/L Standard Deviation 47.5753
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 8	5.415 μmol/L Standard Deviation 42.9500	-6.231 μmol/L Standard Deviation 40.4198	11.791 μmol/L Standard Deviation 64.9910	3.410 μmol/L Standard Deviation 33.9518	8.024 μmol/L Standard Deviation 44.0043
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 12	10.707 μmol/L Standard Deviation 40.2208	6.795 μmol/L Standard Deviation 54.4814	13.881 μmol/L Standard Deviation 55.3332	7.553 μmol/L Standard Deviation 33.4904	2.805 μmol/L Standard Deviation 37.6651
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 16	25.810 μmol/L Standard Deviation 44.1965	8.079 μmol/L Standard Deviation 50.0062	15.357 μmol/L Standard Deviation 59.0311	14.026 μmol/L Standard Deviation 40.5173	21.683 μmol/L Standard Deviation 41.1670
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 20	28.950 μmol/L Standard Deviation 53.8602	4.692 μmol/L Standard Deviation 59.0420	16.048 μmol/L Standard Deviation 63.4346	10.622 μmol/L Standard Deviation 42.1567	10.600 μmol/L Standard Deviation 44.3262
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 24	17.410 μmol/L Standard Deviation 45.0045	9.923 μmol/L Standard Deviation 54.9648	3.683 μmol/L Standard Deviation 58.6977	6.667 μmol/L Standard Deviation 45.2580	6.950 μmol/L Standard Deviation 45.8638
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 32	17.026 μmol/L Standard Deviation 47.8185	2.821 μmol/L Standard Deviation 48.9042	5.800 μmol/L Standard Deviation 56.2017	3.971 μmol/L Standard Deviation 45.1103	17.077 μmol/L Standard Deviation 40.3089
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 36	0.211 μmol/L Standard Deviation 37.5630	-4.868 μmol/L Standard Deviation 49.1419	-10.927 μmol/L Standard Deviation 59.4228	4.735 μmol/L Standard Deviation 42.4309	5.846 μmol/L Standard Deviation 49.4259
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 40	9.730 μmol/L Standard Deviation 43.5295	15.605 μmol/L Standard Deviation 53.8931	9.976 μmol/L Standard Deviation 62.8739	-5.029 μmol/L Standard Deviation 41.2630	7.255 μmol/L Standard Deviation 46.0833
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 44	20.541 μmol/L Standard Deviation 57.9164	7.605 μmol/L Standard Deviation 64.3342	-8.854 μmol/L Standard Deviation 67.3523	1.382 μmol/L Standard Deviation 47.9558	10.675 μmol/L Standard Deviation 50.8963
Changes From Baseline in Biochemistry Parameters During the Study (Bilirubin, Creatinine, Urate) Urate Week 48	8.684 μmol/L Standard Deviation 53.6208	3.895 μmol/L Standard Deviation 48.5831	-3.220 μmol/L Standard Deviation 64.9282	1.853 μmol/L Standard Deviation 54.8762	8.050 μmol/L Standard Deviation 49.1956

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Calcium, chloride, cholesterol, glucose, magnesium, potassium, sodium were measured in millimoles per liter (mmol/L).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 1	-0.034 mmol/L Standard Deviation 0.0810	-0.017 mmol/L Standard Deviation 0.0984	-0.008 mmol/L Standard Deviation 0.0858	-0.002 mmol/L Standard Deviation 0.0990	-0.014 mmol/L Standard Deviation 0.0897
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 4	-0.029 mmol/L Standard Deviation 0.1079	-0.011 mmol/L Standard Deviation 0.1015	-0.021 mmol/L Standard Deviation 0.0973	-0.047 mmol/L Standard Deviation 0.1147	-0.020 mmol/L Standard Deviation 0.0917
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 24	0.011 mmol/L Standard Deviation 0.1019	-0.002 mmol/L Standard Deviation 0.1028	0.015 mmol/L Standard Deviation 0.0845	0.004 mmol/L Standard Deviation 0.0896	0.003 mmol/L Standard Deviation 0.0974
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 32	-0.023 mmol/L Standard Deviation 0.1069	0.000 mmol/L Standard Deviation 0.0952	0.001 mmol/L Standard Deviation 0.1074	-0.017 mmol/L Standard Deviation 0.0932	-0.008 mmol/L Standard Deviation 0.1024
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 40	0.003 mmol/L Standard Deviation 0.0905	0.001 mmol/L Standard Deviation 0.0807	-0.007 mmol/L Standard Deviation 0.1084	-0.019 mmol/L Standard Deviation 0.0809	-0.025 mmol/L Standard Deviation 0.0947
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 1	-0.195 mmol/L Standard Deviation 2.1121	-0.105 mmol/L Standard Deviation 2.5446	-0.674 mmol/L Standard Deviation 4.1388	-0.244 mmol/L Standard Deviation 2.5572	-0.125 mmol/L Standard Deviation 2.3986
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 44	-0.170 mmol/L Standard Deviation 0.8082	-0.176 mmol/L Standard Deviation 1.0874	0.071 mmol/L Standard Deviation 0.9341	-0.218 mmol/L Standard Deviation 0.9150	-0.000 mmol/L Standard Deviation 0.8407
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 36	0.089 mmol/L Standard Deviation 0.9061	0.342 mmol/L Standard Deviation 0.9406	0.234 mmol/L Standard Deviation 1.0379	0.174 mmol/L Standard Deviation 1.0175	0.290 mmol/L Standard Deviation 0.7789
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 28	-0.027 mmol/L Standard Deviation 0.0713	-0.007 mmol/L Standard Deviation 0.0525	-0.018 mmol/L Standard Deviation 0.0678	-0.019 mmol/L Standard Deviation 0.0719	-0.017 mmol/L Standard Deviation 0.0565
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 2	-0.098 mmol/L Standard Deviation 0.2975	0.085 mmol/L Standard Deviation 0.4095	0.002 mmol/L Standard Deviation 0.3327	-0.005 mmol/L Standard Deviation 0.3521	0.027 mmol/L Standard Deviation 0.3074
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 24	-0.095 mmol/L Standard Deviation 0.3308	-0.072 mmol/L Standard Deviation 0.3052	0.030 mmol/L Standard Deviation 0.3844	-0.094 mmol/L Standard Deviation 0.3414	-0.062 mmol/L Standard Deviation 0.2967
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 28	-0.462 mmol/L Standard Deviation 2.2924	-0.658 mmol/L Standard Deviation 1.8494	-0.683 mmol/L Standard Deviation 1.8767	-0.457 mmol/L Standard Deviation 2.3307	-0.575 mmol/L Standard Deviation 2.5609
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 32	-1.077 mmol/L Standard Deviation 1.8692	-0.128 mmol/L Standard Deviation 1.9219	-0.525 mmol/L Standard Deviation 1.8809	-0.441 mmol/L Standard Deviation 1.6732	-0.667 mmol/L Standard Deviation 1.8257
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 44	-0.486 mmol/L Standard Deviation 1.8352	-0.737 mmol/L Standard Deviation 2.0492	-0.878 mmol/L Standard Deviation 1.9390	-0.647 mmol/L Standard Deviation 1.8238	-1.000 mmol/L Standard Deviation 2.4179
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 2	-0.021 mmol/L Standard Deviation 0.0951	0.002 mmol/L Standard Deviation 0.0973	0.009 mmol/L Standard Deviation 0.1304	-0.024 mmol/L Standard Deviation 0.1001	-0.022 mmol/L Standard Deviation 0.0938
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 8	-0.024 mmol/L Standard Deviation 0.0942	-0.006 mmol/L Standard Deviation 0.0926	0.008 mmol/L Standard Deviation 0.1260	-0.004 mmol/L Standard Deviation 0.1105	-0.022 mmol/L Standard Deviation 0.0975
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 12	-0.021 mmol/L Standard Deviation 0.1009	-0.025 mmol/L Standard Deviation 0.1090	0.021 mmol/L Standard Deviation 0.1057	-0.020 mmol/L Standard Deviation 0.1088	-0.025 mmol/L Standard Deviation 0.0923
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 16	0.004 mmol/L Standard Deviation 0.0826	-0.006 mmol/L Standard Deviation 0.1079	0.023 mmol/L Standard Deviation 0.1334	-0.004 mmol/L Standard Deviation 0.1027	0.005 mmol/L Standard Deviation 0.0888
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 20	0.002 mmol/L Standard Deviation 0.0931	0.000 mmol/L Standard Deviation 0.1013	0.017 mmol/L Standard Deviation 0.0999	-0.008 mmol/L Standard Deviation 0.0948	-0.018 mmol/L Standard Deviation 0.0919
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 28	-0.027 mmol/L Standard Deviation 0.1117	0.002 mmol/L Standard Deviation 0.0877	0.009 mmol/L Standard Deviation 0.1068	0.008 mmol/L Standard Deviation 0.0909	-0.021 mmol/L Standard Deviation 0.1043
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 36	-0.013 mmol/L Standard Deviation 0.1172	0.007 mmol/L Standard Deviation 0.0804	-0.005 mmol/L Standard Deviation 0.1096	0.001 mmol/L Standard Deviation 0.0972	-0.015 mmol/L Standard Deviation 0.0936
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 44	-0.027 mmol/L Standard Deviation 0.0920	-0.018 mmol/L Standard Deviation 0.0861	-0.008 mmol/L Standard Deviation 0.1023	-0.019 mmol/L Standard Deviation 0.0839	-0.042 mmol/L Standard Deviation 0.0972
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Calcium Week 48	-0.010 mmol/L Standard Deviation 0.0881	-0.009 mmol/L Standard Deviation 0.1033	-0.014 mmol/L Standard Deviation 0.1126	-0.014 mmol/L Standard Deviation 0.0912	-0.034 mmol/L Standard Deviation 0.0861
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 2	-0.214 mmol/L Standard Deviation 2.1131	0.308 mmol/L Standard Deviation 2.6273	0.093 mmol/L Standard Deviation 2.7500	0.415 mmol/L Standard Deviation 2.5296	-0.439 mmol/L Standard Deviation 2.4192
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 4	-0.293 mmol/L Standard Deviation 1.9525	-0.333 mmol/L Standard Deviation 2.2750	0.000 mmol/L Standard Deviation 2.4792	0.024 mmol/L Standard Deviation 2.6409	0.000 mmol/L Standard Deviation 2.6363
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 8	-0.537 mmol/L Standard Deviation 2.1920	0.615 mmol/L Standard Deviation 2.4346	0.047 mmol/L Standard Deviation 2.6988	0.538 mmol/L Standard Deviation 2.3038	0.683 mmol/L Standard Deviation 2.4025
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 12	0.341 mmol/L Standard Deviation 2.2205	-0.282 mmol/L Standard Deviation 2.3946	0.548 mmol/L Standard Deviation 2.5681	-0.211 mmol/L Standard Deviation 2.3499	0.000 mmol/L Standard Deviation 2.4393
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 16	-0.310 mmol/L Standard Deviation 1.8934	0.026 mmol/L Standard Deviation 2.2837	0.190 mmol/L Standard Deviation 2.0864	-0.184 mmol/L Standard Deviation 2.2644	-0.268 mmol/L Standard Deviation 2.1334
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 20	-0.325 mmol/L Standard Deviation 2.4640	-0.538 mmol/L Standard Deviation 2.1502	0.262 mmol/L Standard Deviation 2.3484	0.162 mmol/L Standard Deviation 2.6616	0.075 mmol/L Standard Deviation 2.3685
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 24	-0.615 mmol/L Standard Deviation 2.0081	-0.128 mmol/L Standard Deviation 2.5462	-0.390 mmol/L Standard Deviation 2.6351	-0.306 mmol/L Standard Deviation 2.1885	-0.050 mmol/L Standard Deviation 2.5415
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 28	0.128 mmol/L Standard Deviation 2.3190	0.000 mmol/L Standard Deviation 2.6913	0.195 mmol/L Standard Deviation 2.3154	0.086 mmol/L Standard Deviation 2.5365	0.250 mmol/L Standard Deviation 2.5090
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 32	-0.154 mmol/L Standard Deviation 2.2069	0.436 mmol/L Standard Deviation 2.3708	0.500 mmol/L Standard Deviation 2.2072	0.794 mmol/L Standard Deviation 2.3196	0.282 mmol/L Standard Deviation 2.0641
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 36	0.237 mmol/L Standard Deviation 1.9923	0.684 mmol/L Standard Deviation 2.4285	0.732 mmol/L Standard Deviation 1.9239	0.294 mmol/L Standard Deviation 2.5999	0.205 mmol/L Standard Deviation 2.4299
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 40	-0.054 mmol/L Standard Deviation 2.5380	0.263 mmol/L Standard Deviation 2.6271	0.707 mmol/L Standard Deviation 2.4418	0.824 mmol/L Standard Deviation 2.4676	0.500 mmol/L Standard Deviation 2.4495
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 44	0.135 mmol/L Standard Deviation 1.9027	0.579 mmol/L Standard Deviation 2.6977	0.756 mmol/L Standard Deviation 2.1069	0.882 mmol/L Standard Deviation 2.8044	0.200 mmol/L Standard Deviation 2.5840
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Chloride Week 48	0.605 mmol/L Standard Deviation 2.0994	0.737 mmol/L Standard Deviation 2.8158	1.024 mmol/L Standard Deviation 2.4545	0.971 mmol/L Standard Deviation 2.5044	0.725 mmol/L Standard Deviation 2.7826
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 1	-0.254 mmol/L Standard Deviation 0.4371	0.032 mmol/L Standard Deviation 0.4307	0.244 mmol/L Standard Deviation 0.5220	0.105 mmol/L Standard Deviation 0.4690	0.102 mmol/L Standard Deviation 0.3965
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 2	-0.224 mmol/L Standard Deviation 0.4154	0.108 mmol/L Standard Deviation 0.5132	0.295 mmol/L Standard Deviation 0.5178	0.054 mmol/L Standard Deviation 0.5441	0.222 mmol/L Standard Deviation 0.6101
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 4	-0.198 mmol/L Standard Deviation 0.6334	-0.023 mmol/L Standard Deviation 0.5905	0.210 mmol/L Standard Deviation 0.8027	0.093 mmol/L Standard Deviation 0.6525	0.151 mmol/L Standard Deviation 0.4178
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 8	-0.190 mmol/L Standard Deviation 0.6935	-0.023 mmol/L Standard Deviation 0.5770	0.284 mmol/L Standard Deviation 0.8012	0.074 mmol/L Standard Deviation 0.7920	0.061 mmol/L Standard Deviation 0.6268
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 12	-0.124 mmol/L Standard Deviation 0.6719	0.013 mmol/L Standard Deviation 0.7473	0.117 mmol/L Standard Deviation 0.7616	0.005 mmol/L Standard Deviation 0.6045	0.212 mmol/L Standard Deviation 0.7491
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 16	0.095 mmol/L Standard Deviation 0.6811	0.184 mmol/L Standard Deviation 0.6378	0.138 mmol/L Standard Deviation 0.6814	0.068 mmol/L Standard Deviation 0.6014	0.249 mmol/L Standard Deviation 0.7075
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 20	0.053 mmol/L Standard Deviation 0.7609	0.126 mmol/L Standard Deviation 0.6889	0.186 mmol/L Standard Deviation 0.9669	0.116 mmol/L Standard Deviation 0.7101	0.115 mmol/L Standard Deviation 0.7718
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 24	0.041 mmol/L Standard Deviation 0.8729	0.013 mmol/L Standard Deviation 0.8673	0.127 mmol/L Standard Deviation 1.0682	-0.003 mmol/L Standard Deviation 0.6984	0.077 mmol/L Standard Deviation 0.5686
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 28	-0.044 mmol/L Standard Deviation 0.9797	-0.037 mmol/L Standard Deviation 0.8930	0.076 mmol/L Standard Deviation 1.1434	-0.037 mmol/L Standard Deviation 0.5801	0.100 mmol/L Standard Deviation 0.5923
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 32	-0.085 mmol/L Standard Deviation 0.8540	-0.079 mmol/L Standard Deviation 0.8918	0.175 mmol/L Standard Deviation 1.0895	-0.050 mmol/L Standard Deviation 0.5945	0.256 mmol/L Standard Deviation 0.6920
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 36	0.005 mmol/L Standard Deviation 0.7322	0.024 mmol/L Standard Deviation 0.7951	0.117 mmol/L Standard Deviation 0.8408	-0.038 mmol/L Standard Deviation 0.6597	0.144 mmol/L Standard Deviation 0.7950
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 40	-0.103 mmol/L Standard Deviation 0.7541	-0.118 mmol/L Standard Deviation 0.9109	0.183 mmol/L Standard Deviation 0.8947	-0.135 mmol/L Standard Deviation 0.7454	0.110 mmol/L Standard Deviation 0.7824
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Cholesterol Week 48	-0.282 mmol/L Standard Deviation 0.7891	-0.279 mmol/L Standard Deviation 0.8348	0.012 mmol/L Standard Deviation 0.8883	-0.253 mmol/L Standard Deviation 0.6653	-0.083 mmol/L Standard Deviation 0.5817
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 1	0.307 mmol/L Standard Deviation 1.3942	0.103 mmol/L Standard Deviation 0.7027	0.077 mmol/L Standard Deviation 1.1366	0.173 mmol/L Standard Deviation 1.0232	-0.060 mmol/L Standard Deviation 0.8445
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 2	0.062 mmol/L Standard Deviation 0.6681	0.013 mmol/L Standard Deviation 0.8348	0.221 mmol/L Standard Deviation 0.9652	0.129 mmol/L Standard Deviation 1.2364	0.190 mmol/L Standard Deviation 0.8938
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 4	0.298 mmol/L Standard Deviation 0.8575	0.015 mmol/L Standard Deviation 0.6888	0.248 mmol/L Standard Deviation 0.7693	0.249 mmol/L Standard Deviation 1.0659	0.134 mmol/L Standard Deviation 0.7428
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 8	0.112 mmol/L Standard Deviation 0.9127	0.308 mmol/L Standard Deviation 0.7696	0.258 mmol/L Standard Deviation 0.9254	0.344 mmol/L Standard Deviation 0.6939	0.256 mmol/L Standard Deviation 0.7075
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 12	0.110 mmol/L Standard Deviation 0.9146	0.005 mmol/L Standard Deviation 0.6117	0.188 mmol/L Standard Deviation 0.7533	0.111 mmol/L Standard Deviation 0.6455	-0.124 mmol/L Standard Deviation 0.6636
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 16	0.176 mmol/L Standard Deviation 0.8363	0.195 mmol/L Standard Deviation 0.6316	0.424 mmol/L Standard Deviation 1.1521	0.276 mmol/L Standard Deviation 0.8280	0.398 mmol/L Standard Deviation 0.8332
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 20	0.208 mmol/L Standard Deviation 1.0560	0.315 mmol/L Standard Deviation 1.0225	0.267 mmol/L Standard Deviation 1.0132	0.632 mmol/L Standard Deviation 0.9741	0.165 mmol/L Standard Deviation 1.0366
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 24	0.018 mmol/L Standard Deviation 1.1856	0.092 mmol/L Standard Deviation 0.7747	0.328 mmol/L Standard Deviation 0.8554	0.061 mmol/L Standard Deviation 1.0462	0.037 mmol/L Standard Deviation 0.6295
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 28	0.246 mmol/L Standard Deviation 1.1812	0.263 mmol/L Standard Deviation 0.9371	0.322 mmol/L Standard Deviation 1.1372	0.263 mmol/L Standard Deviation 1.0053	0.262 mmol/L Standard Deviation 0.6412
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 32	0.333 mmol/L Standard Deviation 1.2671	0.236 mmol/L Standard Deviation 0.7013	0.570 mmol/L Standard Deviation 1.0301	0.356 mmol/L Standard Deviation 1.1021	0.203 mmol/L Standard Deviation 0.5945
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 40	0.143 mmol/L Standard Deviation 1.0885	0.245 mmol/L Standard Deviation 1.1081	0.507 mmol/L Standard Deviation 1.1257	0.203 mmol/L Standard Deviation 0.7420	0.125 mmol/L Standard Deviation 0.7016
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 44	0.222 mmol/L Standard Deviation 1.4919	0.200 mmol/L Standard Deviation 1.0950	0.185 mmol/L Standard Deviation 0.8688	0.303 mmol/L Standard Deviation 1.2760	0.197 mmol/L Standard Deviation 0.8966
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Glucose Week 48	-0.013 mmol/L Standard Deviation 1.2512	0.045 mmol/L Standard Deviation 0.8472	0.141 mmol/L Standard Deviation 0.9341	0.276 mmol/L Standard Deviation 1.0841	0.100 mmol/L Standard Deviation 0.7835
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 1	-0.010 mmol/L Standard Deviation 0.0672	-0.007 mmol/L Standard Deviation 0.0676	0.002 mmol/L Standard Deviation 0.0694	-0.014 mmol/L Standard Deviation 0.0573	-0.015 mmol/L Standard Deviation 0.0680
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 2	-0.004 mmol/L Standard Deviation 0.0795	0.008 mmol/L Standard Deviation 0.0745	-0.011 mmol/L Standard Deviation 0.0771	-0.019 mmol/L Standard Deviation 0.0624	-0.007 mmol/L Standard Deviation 0.0680
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 4	-0.022 mmol/L Standard Deviation 0.0606	0.009 mmol/L Standard Deviation 0.0725	-0.012 mmol/L Standard Deviation 0.0789	-0.020 mmol/L Standard Deviation 0.0712	-0.005 mmol/L Standard Deviation 0.0998
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 8	-0.016 mmol/L Standard Deviation 0.0706	-0.008 mmol/L Standard Deviation 0.0593	-0.013 mmol/L Standard Deviation 0.0819	-0.015 mmol/L Standard Deviation 0.0706	-0.006 mmol/L Standard Deviation 0.0624
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 12	0.010 mmol/L Standard Deviation 0.0797	0.008 mmol/L Standard Deviation 0.0847	-0.011 mmol/L Standard Deviation 0.0733	-0.001 mmol/L Standard Deviation 0.0660	0.003 mmol/L Standard Deviation 0.0730
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 16	-0.002 mmol/L Standard Deviation 0.0742	0.003 mmol/L Standard Deviation 0.0823	-0.021 mmol/L Standard Deviation 0.0659	-0.009 mmol/L Standard Deviation 0.0629	-0.002 mmol/L Standard Deviation 0.0731
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 20	-0.007 mmol/L Standard Deviation 0.0811	-0.012 mmol/L Standard Deviation 0.0728	-0.018 mmol/L Standard Deviation 0.0659	-0.005 mmol/L Standard Deviation 0.0724	-0.009 mmol/L Standard Deviation 0.0636
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 24	-0.005 mmol/L Standard Deviation 0.0757	-0.004 mmol/L Standard Deviation 0.0572	-0.014 mmol/L Standard Deviation 0.0732	-0.009 mmol/L Standard Deviation 0.0559	-0.016 mmol/L Standard Deviation 0.0664
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 32	-0.023 mmol/L Standard Deviation 0.0727	-0.016 mmol/L Standard Deviation 0.0641	-0.016 mmol/L Standard Deviation 0.0603	-0.012 mmol/L Standard Deviation 0.0670	-0.013 mmol/L Standard Deviation 0.0572
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 36	-0.015 mmol/L Standard Deviation 0.0694	-0.001 mmol/L Standard Deviation 0.0596	-0.031 mmol/L Standard Deviation 0.0698	-0.004 mmol/L Standard Deviation 0.0534	-0.007 mmol/L Standard Deviation 0.0563
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 40	-0.032 mmol/L Standard Deviation 0.0681	-0.007 mmol/L Standard Deviation 0.0541	-0.014 mmol/L Standard Deviation 0.0754	-0.024 mmol/L Standard Deviation 0.0636	-0.009 mmol/L Standard Deviation 0.0684
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 44	-0.024 mmol/L Standard Deviation 0.0677	-0.000 mmol/L Standard Deviation 0.0597	-0.009 mmol/L Standard Deviation 0.0685	-0.024 mmol/L Standard Deviation 0.0668	-0.016 mmol/L Standard Deviation 0.0667
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Magnesium Week 48	-0.004 mmol/L Standard Deviation 0.0633	-0.004 mmol/L Standard Deviation 0.0546	-0.014 mmol/L Standard Deviation 0.0569	-0.006 mmol/L Standard Deviation 0.0616	-0.009 mmol/L Standard Deviation 0.0648
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 1	-0.095 mmol/L Standard Deviation 0.2701	0.089 mmol/L Standard Deviation 0.3608	0.081 mmol/L Standard Deviation 0.4289	-0.017 mmol/L Standard Deviation 0.3098	-0.062 mmol/L Standard Deviation 0.3216
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 4	-0.080 mmol/L Standard Deviation 0.2522	0.008 mmol/L Standard Deviation 0.3821	0.026 mmol/L Standard Deviation 0.2632	0.024 mmol/L Standard Deviation 0.4030	-0.063 mmol/L Standard Deviation 0.2853
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 8	-0.056 mmol/L Standard Deviation 0.2907	0.069 mmol/L Standard Deviation 0.3221	0.014 mmol/L Standard Deviation 0.3306	-0.010 mmol/L Standard Deviation 0.3135	0.000 mmol/L Standard Deviation 0.2520
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 12	-0.073 mmol/L Standard Deviation 0.3217	0.033 mmol/L Standard Deviation 0.3398	-0.024 mmol/L Standard Deviation 0.3192	-0.082 mmol/L Standard Deviation 0.3074	-0.080 mmol/L Standard Deviation 0.2977
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 16	-0.086 mmol/L Standard Deviation 0.3258	0.083 mmol/L Standard Deviation 0.3112	0.012 mmol/L Standard Deviation 0.3651	-0.037 mmol/L Standard Deviation 0.3035	-0.020 mmol/L Standard Deviation 0.2713
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 20	-0.092 mmol/L Standard Deviation 0.3846	0.031 mmol/L Standard Deviation 0.3381	0.055 mmol/L Standard Deviation 0.3494	-0.019 mmol/L Standard Deviation 0.3627	0.000 mmol/L Standard Deviation 0.2774
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 28	-0.077 mmol/L Standard Deviation 0.3141	0.105 mmol/L Standard Deviation 0.3616	0.063 mmol/L Standard Deviation 0.4265	-0.003 mmol/L Standard Deviation 0.3312	-0.030 mmol/L Standard Deviation 0.3480
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 32	-0.062 mmol/L Standard Deviation 0.3306	0.069 mmol/L Standard Deviation 0.3621	0.023 mmol/L Standard Deviation 0.4154	0.056 mmol/L Standard Deviation 0.2688	0.046 mmol/L Standard Deviation 0.3094
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 36	-0.092 mmol/L Standard Deviation 0.3388	0.045 mmol/L Standard Deviation 0.3689	0.066 mmol/L Standard Deviation 0.4316	0.003 mmol/L Standard Deviation 0.3205	0.033 mmol/L Standard Deviation 0.3359
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 40	-0.092 mmol/L Standard Deviation 0.3616	0.089 mmol/L Standard Deviation 0.3826	0.024 mmol/L Standard Deviation 0.3484	-0.003 mmol/L Standard Deviation 0.3407	-0.017 mmol/L Standard Deviation 0.3456
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 44	-0.119 mmol/L Standard Deviation 0.2933	0.029 mmol/L Standard Deviation 0.3571	0.068 mmol/L Standard Deviation 0.4344	0.094 mmol/L Standard Deviation 0.3084	-0.035 mmol/L Standard Deviation 0.3009
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Potassium Week 48	-0.137 mmol/L Standard Deviation 0.3627	-0.053 mmol/L Standard Deviation 0.3244	-0.032 mmol/L Standard Deviation 0.3274	0.003 mmol/L Standard Deviation 0.4123	-0.027 mmol/L Standard Deviation 0.3250
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 1	-0.146 mmol/L Standard Deviation 1.5582	-0.184 mmol/L Standard Deviation 1.7531	0.000 mmol/L Standard Deviation 2.0471	-0.610 mmol/L Standard Deviation 2.0722	-0.375 mmol/L Standard Deviation 2.1326
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 2	-0.500 mmol/L Standard Deviation 1.6417	-0.513 mmol/L Standard Deviation 1.8191	-0.209 mmol/L Standard Deviation 1.9341	-0.244 mmol/L Standard Deviation 2.0221	-0.341 mmol/L Standard Deviation 2.1167
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 4	-0.732 mmol/L Standard Deviation 1.8442	-0.385 mmol/L Standard Deviation 1.6482	-0.214 mmol/L Standard Deviation 2.3430	-0.707 mmol/L Standard Deviation 2.0155	-0.805 mmol/L Standard Deviation 1.8196
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 8	-0.854 mmol/L Standard Deviation 2.0070	-0.410 mmol/L Standard Deviation 1.3711	-0.860 mmol/L Standard Deviation 2.2316	-0.359 mmol/L Standard Deviation 1.7394	-0.463 mmol/L Standard Deviation 2.2924
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 12	-0.512 mmol/L Standard Deviation 1.8858	-0.513 mmol/L Standard Deviation 1.4845	-0.619 mmol/L Standard Deviation 2.0357	-0.632 mmol/L Standard Deviation 2.1738	-0.854 mmol/L Standard Deviation 2.3512
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 16	-0.738 mmol/L Standard Deviation 1.8086	-0.211 mmol/L Standard Deviation 1.7423	-0.714 mmol/L Standard Deviation 1.7708	-0.842 mmol/L Standard Deviation 2.3656	-0.780 mmol/L Standard Deviation 1.7250
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 20	-0.675 mmol/L Standard Deviation 1.7155	-0.538 mmol/L Standard Deviation 1.4482	-0.857 mmol/L Standard Deviation 2.1928	-0.595 mmol/L Standard Deviation 2.1661	-0.775 mmol/L Standard Deviation 1.9147
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 24	-0.821 mmol/L Standard Deviation 1.7751	-0.487 mmol/L Standard Deviation 1.5196	-0.463 mmol/L Standard Deviation 2.0137	-0.472 mmol/L Standard Deviation 1.8124	-0.725 mmol/L Standard Deviation 1.7393
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 36	-0.711 mmol/L Standard Deviation 2.0122	-0.263 mmol/L Standard Deviation 1.8986	-0.512 mmol/L Standard Deviation 1.8725	-0.618 mmol/L Standard Deviation 1.9850	-0.436 mmol/L Standard Deviation 2.2337
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 40	-0.432 mmol/L Standard Deviation 2.1153	-0.474 mmol/L Standard Deviation 1.6397	-0.512 mmol/L Standard Deviation 2.1578	-0.882 mmol/L Standard Deviation 1.9812	-0.950 mmol/L Standard Deviation 2.0248
Changes From Baseline in Biochemistry Parameters During the Study (Calcium, Chloride, Cholesterol, Glucose, Magnesium, Potassium, Sodium) Sodium Week 48	-0.237 mmol/L Standard Deviation 1.7772	-0.763 mmol/L Standard Deviation 1.8074	-0.732 mmol/L Standard Deviation 1.8845	-0.706 mmol/L Standard Deviation 1.5281	-0.750 mmol/L Standard Deviation 2.1334

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Urea nitrogen was measured in millimoles per liter (mmol/L).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 1	-0.093 mmol/L Standard Deviation 1.0815	0.126 mmol/L Standard Deviation 1.2116	-0.123 mmol/L Standard Deviation 1.0989	-0.012 mmol/L Standard Deviation 1.0900	0.173 mmol/L Standard Deviation 1.5513
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 8	0.007 mmol/L Standard Deviation 0.9936	0.023 mmol/L Standard Deviation 1.1685	-0.070 mmol/L Standard Deviation 1.1143	-0.379 mmol/L Standard Deviation 1.2316	0.080 mmol/L Standard Deviation 1.1265
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 20	-0.207 mmol/L Standard Deviation 1.2670	-0.490 mmol/L Standard Deviation 1.0901	-0.064 mmol/L Standard Deviation 1.2916	-0.357 mmol/L Standard Deviation 1.1572	-0.035 mmol/L Standard Deviation 1.3202
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 24	-0.256 mmol/L Standard Deviation 1.1378	-0.523 mmol/L Standard Deviation 1.1235	-0.232 mmol/L Standard Deviation 1.4951	-0.289 mmol/L Standard Deviation 1.1369	-0.138 mmol/L Standard Deviation 1.2245
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 44	-0.105 mmol/L Standard Deviation 1.3389	-0.047 mmol/L Standard Deviation 1.3456	-0.054 mmol/L Standard Deviation 1.1276	-0.229 mmol/L Standard Deviation 1.1979	0.210 mmol/L Standard Deviation 1.2264
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 2	0.386 mmol/L Standard Deviation 1.8183	-0.208 mmol/L Standard Deviation 1.1329	-0.047 mmol/L Standard Deviation 1.0359	0.024 mmol/L Standard Deviation 1.1762	0.212 mmol/L Standard Deviation 1.3064
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 4	0.027 mmol/L Standard Deviation 1.3217	0.013 mmol/L Standard Deviation 1.1307	0.083 mmol/L Standard Deviation 1.1244	-0.224 mmol/L Standard Deviation 1.1449	0.007 mmol/L Standard Deviation 1.2384
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 12	-0.166 mmol/L Standard Deviation 1.2654	-0.244 mmol/L Standard Deviation 1.1740	-0.231 mmol/L Standard Deviation 1.3357	-0.429 mmol/L Standard Deviation 1.1733	-0.151 mmol/L Standard Deviation 1.2426
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 16	-0.133 mmol/L Standard Deviation 1.0656	-0.087 mmol/L Standard Deviation 0.9793	-0.200 mmol/L Standard Deviation 1.3083	-0.218 mmol/L Standard Deviation 1.0747	0.012 mmol/L Standard Deviation 1.1996
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 28	-0.267 mmol/L Standard Deviation 1.3487	-0.287 mmol/L Standard Deviation 1.0992	0.012 mmol/L Standard Deviation 1.3020	-0.263 mmol/L Standard Deviation 1.1835	-0.082 mmol/L Standard Deviation 1.3239
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 32	-0.097 mmol/L Standard Deviation 1.0396	-0.141 mmol/L Standard Deviation 1.3098	-0.200 mmol/L Standard Deviation 1.1266	-0.326 mmol/L Standard Deviation 1.1199	0.082 mmol/L Standard Deviation 1.1841
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 36	-0.203 mmol/L Standard Deviation 1.0579	-0.308 mmol/L Standard Deviation 1.1757	0.015 mmol/L Standard Deviation 1.1094	-0.247 mmol/L Standard Deviation 1.1683	-0.018 mmol/L Standard Deviation 1.1014
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 40	-0.214 mmol/L Standard Deviation 1.2537	0.192 mmol/L Standard Deviation 1.3690	0.068 mmol/L Standard Deviation 1.1230	-0.132 mmol/L Standard Deviation 1.1834	0.283 mmol/L Standard Deviation 1.3435
Changes From Baseline in Biochemistry Parameters During the Study (Urea Nitrogen) Week 48	-0.111 mmol/L Standard Deviation 1.4431	-0.113 mmol/L Standard Deviation 1.1796	-0.222 mmol/L Standard Deviation 1.4085	-0.285 mmol/L Standard Deviation 1.2611	0.088 mmol/L Standard Deviation 1.4580

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP. Number of participants reflect those with non-missing urinalysis results during the study.

Erythrocytes, leukocytes, renal epithelial casts, squamous epithelial cells, transitional epithelial cells were measured in cells per high power field (cells/HPF).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=2 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=6 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=5 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=7 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=4 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 8	—	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.8165	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 1.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 16	-55.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.800 cells/HPF Standard Deviation 1.7889	0.500 cells/HPF Standard Deviation 1.7321	0.000 cells/HPF Standard Deviation 0.0000	2.500 cells/HPF Standard Deviation 3.5355
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 32	-27.500 cells/HPF Standard Deviation 38.8909	0.000 cells/HPF Standard Deviation 0.0000	0.250 cells/HPF Standard Deviation 0.5000	0.000 cells/HPF Standard Deviation 0.0000	2.000 cells/HPF Standard Deviation 3.4641
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 36	-55.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.250 cells/HPF Standard Deviation 0.5000	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	-1.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 28	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 32	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 16	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	-0.200 cells/HPF Standard Deviation 1.7889	33.750 cells/HPF Standard Deviation 67.5000	-0.400 cells/HPF Standard Deviation 0.8944	0.500 cells/HPF Standard Deviation 0.7071
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 20	0.000 cells/HPF Standard Deviation 2.8284	3.000 cells/HPF Standard Deviation 6.0000	57.800 cells/HPF Standard Deviation 145.4036	0.667 cells/HPF Standard Deviation 1.5055	-6.750 cells/HPF Standard Deviation 14.8633
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 24	—	2.750 cells/HPF Standard Deviation 4.8563	-6.500 cells/HPF Standard Deviation 13.0000	2.286 cells/HPF Standard Deviation 4.8206	0.333 cells/HPF Standard Deviation 0.5774
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 40	—	-0.500 cells/HPF Standard Deviation 2.5166	-7.500 cells/HPF Standard Deviation 15.0000	1.500 cells/HPF Standard Deviation 3.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 44	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.400 cells/HPF Standard Deviation 0.8944	-1.400 cells/HPF Standard Deviation 3.1305	-0.500 cells/HPF Standard Deviation 1.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 48	0.000 cells/HPF Standard Deviation 0.0000	8.000 cells/HPF Standard Deviation 21.6148	69.500 cells/HPF Standard Deviation 139.0000	-1.000 cells/HPF Standard Deviation 1.7321	0.250 cells/HPF Standard Deviation 0.5000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 1	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 2	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 4	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 8	—	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 12	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 16	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 24	—	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 28	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 32	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 36	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.167 cells/HPF Standard Deviation 0.4082	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 40	—	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 44	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 48	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 1	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.250 cells/HPF Standard Deviation 1.2583	3.000 cells/HPF Standard Deviation 5.1962	-0.200 cells/HPF Standard Deviation 0.4472	-0.333 cells/HPF Standard Deviation 0.5774
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 2	1.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	-8.000 cells/HPF Standard Deviation 14.6969	-0.250 cells/HPF Standard Deviation 3.6856	0.000 cells/HPF Standard Deviation 0.0000	-1.667 cells/HPF Standard Deviation 1.5275
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 4	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	-1.800 cells/HPF Standard Deviation 7.1554	0.000 cells/HPF Standard Deviation 0.0000	1.000 cells/HPF Standard Deviation 1.4142
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 8	—	0.000 cells/HPF Standard Deviation 0.0000	0.500 cells/HPF Standard Deviation 1.0000	0.000 cells/HPF Standard Deviation 0.0000	0.333 cells/HPF Standard Deviation 0.5774
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 16	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	-2.750 cells/HPF Standard Deviation 5.5000	-0.200 cells/HPF Standard Deviation 0.4472	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 20	1.000 cells/HPF Standard Deviation 1.4142	-2.750 cells/HPF Standard Deviation 5.5000	-1.400 cells/HPF Standard Deviation 5.6391	-0.167 cells/HPF Standard Deviation 0.9832	-0.750 cells/HPF Standard Deviation 0.9574
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 24	—	1.000 cells/HPF Standard Deviation 1.4142	1.000 cells/HPF Standard Deviation 2.0000	-0.286 cells/HPF Standard Deviation 0.4880	1.333 cells/HPF Standard Deviation 4.1633
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 28	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	-3.000 cells/HPF Standard Deviation 6.0000	0.600 cells/HPF Standard Deviation 1.3416	-0.250 cells/HPF Standard Deviation 0.5000	-1.667 cells/HPF Standard Deviation 1.5275
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 32	0.500 cells/HPF Standard Deviation 0.7071	0.000 cells/HPF Standard Deviation 0.0000	0.500 cells/HPF Standard Deviation 1.0000	-0.667 cells/HPF Standard Deviation 0.8165	-0.500 cells/HPF Standard Deviation 0.7071
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 36	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 40	—	-2.750 cells/HPF Standard Deviation 5.5000	0.750 cells/HPF Standard Deviation 1.5000	0.000 cells/HPF Standard Deviation 0.0000	-0.500 cells/HPF Standard Deviation 0.7071
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 44	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	-1.000 cells/HPF Standard Deviation 2.2361	0.600 cells/HPF Standard Deviation 1.3416	-0.250 cells/HPF Standard Deviation 0.5000	-0.500 cells/HPF Standard Deviation 0.7071
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 48	0.000 cells/HPF Standard Deviation 0.0000	0.667 cells/HPF Standard Deviation 1.6330	1.250 cells/HPF Standard Deviation 1.8930	0.333 cells/HPF Standard Deviation 0.5774	-1.000 cells/HPF Standard Deviation 1.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 1	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 2	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 4	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 8	—	1.000 cells/HPF Standard Deviation 1.7321	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 12	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.200 cells/HPF Standard Deviation 0.4472	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 16	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.400 cells/HPF Standard Deviation 0.8944	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 20	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 24	—	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 36	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.167 cells/HPF Standard Deviation 0.4082	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 40	—	0.250 cells/HPF Standard Deviation 0.5000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 44	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Transitional Epithelial Cells Week 48	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 1	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	2.750 cells/HPF Standard Deviation 6.1847	-7.667 cells/HPF Standard Deviation 13.2791	-0.200 cells/HPF Standard Deviation 1.0954	0.667 cells/HPF Standard Deviation 1.1547
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 2	2.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	-2.500 cells/HPF Standard Deviation 2.0817	-3.000 cells/HPF Standard Deviation 6.6833	-0.250 cells/HPF Standard Deviation 0.5000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 4	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	-4.600 cells/HPF Standard Deviation 10.2372	0.250 cells/HPF Standard Deviation 0.5000	2.000 cells/HPF Standard Deviation 2.8284
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 8	—	0.000 cells/HPF Standard Deviation 0.0000	-1.500 cells/HPF Standard Deviation 3.6968	0.000 cells/HPF Standard Deviation 0.0000	4.000 cells/HPF Standard Deviation 6.9282
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 44	-55.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.400 cells/HPF Standard Deviation 0.8944	-0.250 cells/HPF Standard Deviation 1.2583	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 48	-27.500 cells/HPF Standard Deviation 38.8909	0.167 cells/HPF Standard Deviation 0.4082	1.750 cells/HPF Standard Deviation 3.5000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.8165
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 1	-55.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.750 cells/HPF Standard Deviation 0.9574	0.333 cells/HPF Standard Deviation 0.5774	0.000 cells/HPF Standard Deviation 0.0000	0.333 cells/HPF Standard Deviation 0.5774
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 2	-54.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	-0.500 cells/HPF Standard Deviation 0.5774	0.250 cells/HPF Standard Deviation 0.5000	0.000 cells/HPF Standard Deviation 0.0000	1.333 cells/HPF Standard Deviation 2.5166
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 4	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	3.333 cells/HPF Standard Deviation 5.7735	0.000 cells/HPF Standard Deviation 0.7071	0.250 cells/HPF Standard Deviation 0.5000	-0.500 cells/HPF Standard Deviation 0.7071
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 12	-23.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.0000	0.800 cells/HPF Standard Deviation 1.3038	0.000 cells/HPF Standard Deviation 0.0000	-0.333 cells/HPF Standard Deviation 0.5774
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 20	-30.000 cells/HPF Standard Deviation 35.3553	0.000 cells/HPF Standard Deviation 0.0000	0.400 cells/HPF Standard Deviation 1.1402	0.000 cells/HPF Standard Deviation 0.0000	0.250 cells/HPF Standard Deviation 0.5000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 24	—	-0.250 cells/HPF Standard Deviation 0.5000	0.250 cells/HPF Standard Deviation 0.5000	-0.143 cells/HPF Standard Deviation 0.8997	1.000 cells/HPF Standard Deviation 2.6458
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 28	-5.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation 0.8165	0.400 cells/HPF Standard Deviation 1.5166	0.000 cells/HPF Standard Deviation 0.0000	2.333 cells/HPF Standard Deviation 5.7735
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Erythrocytes Week 40	—	-0.250 cells/HPF Standard Deviation 0.5000	0.750 cells/HPF Standard Deviation 1.5000	-0.250 cells/HPF Standard Deviation 0.5000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 12	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	1.667 cells/HPF Standard Deviation 4.7258	13.500 cells/HPF Standard Deviation 26.3376	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 28	-2.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	-0.750 cells/HPF Standard Deviation 0.9574	-5.400 cells/HPF Standard Deviation 12.0748	0.000 cells/HPF Standard Deviation 0.0000	2.333 cells/HPF Standard Deviation 4.0415
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 32	0.000 cells/HPF Standard Deviation 0.0000	3.333 cells/HPF Standard Deviation 5.7735	-6.500 cells/HPF Standard Deviation 13.0000	-1.333 cells/HPF Standard Deviation 1.6330	1.333 cells/HPF Standard Deviation 2.3094
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Leukocytes Week 36	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.667 cells/HPF Standard Deviation 2.7325	0.000 cells/HPF Standard Deviation 0.0000	24.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Renal Epithelial Casts Week 20	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000	0.000 cells/HPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Erythrocytes, Leukocytes, Renal Epithelial Casts, Squamous Epithelial Cells, Transitional Epithelial Cells) Squamous Epithelial Cells Week 12	0.000 cells/HPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	-4.333 cells/HPF Standard Deviation 7.5056	-2.200 cells/HPF Standard Deviation 5.4955	0.000 cells/HPF Standard Deviation 0.0000	0.333 cells/HPF Standard Deviation 0.5774

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP. Number of participants reflect those with non-missing urinalysis results during the study.

Hyaline casts was measured in cells per low power field (cells/LPF).

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=2 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=6 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=5 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=7 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=4 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 1	0.000 cells/LPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/LPF Standard Deviation 0.0000	1.000 cells/LPF Standard Deviation 1.7321	-0.200 cells/LPF Standard Deviation 0.4472	0.000 cells/LPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 2	0.000 cells/LPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.250 cells/LPF Standard Deviation 0.5000	1.000 cells/LPF Standard Deviation 1.1547	-0.250 cells/LPF Standard Deviation 0.5000	0.333 cells/LPF Standard Deviation 0.5774
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 4	0.000 cells/LPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/LPF Standard Deviation 0.0000	-0.800 cells/LPF Standard Deviation 1.0954	-0.250 cells/LPF Standard Deviation 0.5000	0.000 cells/LPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 8	—	0.333 cells/LPF Standard Deviation 0.5774	0.250 cells/LPF Standard Deviation 0.5000	0.000 cells/LPF Standard Deviation 0.0000	0.000 cells/LPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 12	0.000 cells/LPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/LPF Standard Deviation 0.0000	5.000 cells/LPF Standard Deviation 11.1803	0.000 cells/LPF Standard Deviation 0.0000	0.000 cells/LPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 16	0.000 cells/LPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/LPF Standard Deviation 0.0000	0.500 cells/LPF Standard Deviation 1.0000	0.000 cells/LPF Standard Deviation 0.0000	0.500 cells/LPF Standard Deviation 0.7071
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 20	0.000 cells/LPF Standard Deviation 0.0000	0.000 cells/LPF Standard Deviation 0.0000	-0.600 cells/LPF Standard Deviation 0.8944	1.500 cells/LPF Standard Deviation 3.6742	-0.750 cells/LPF Standard Deviation 1.5000
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 24	—	0.000 cells/LPF Standard Deviation 0.0000	-0.250 cells/LPF Standard Deviation 0.5000	0.857 cells/LPF Standard Deviation 2.2678	0.333 cells/LPF Standard Deviation 0.5774
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 28	0.000 cells/LPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/LPF Standard Deviation 0.0000	-0.400 cells/LPF Standard Deviation 0.8944	0.000 cells/LPF Standard Deviation 0.0000	0.000 cells/LPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 32	0.000 cells/LPF Standard Deviation 0.0000	0.000 cells/LPF Standard Deviation 0.0000	1.250 cells/LPF Standard Deviation 2.5000	0.000 cells/LPF Standard Deviation 0.0000	13.333 cells/LPF Standard Deviation 23.0940
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 36	0.000 cells/LPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/LPF Standard Deviation 0.0000	0.000 cells/LPF Standard Deviation 0.0000	0.000 cells/LPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.000 cells/LPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 48	0.000 cells/LPF Standard Deviation 0.0000	1.167 cells/LPF Standard Deviation 2.8577	0.000 cells/LPF Standard Deviation 0.0000	0.000 cells/LPF Standard Deviation 0.0000	-0.250 cells/LPF Standard Deviation 0.5000
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 40	—	0.000 cells/LPF Standard Deviation 0.0000	-0.500 cells/LPF Standard Deviation 1.0000	0.000 cells/LPF Standard Deviation 0.0000	0.000 cells/LPF Standard Deviation 0.0000
Changes From Baseline in Urinalysis Parameters During the Study (Hyaline Casts) Week 44	0.000 cells/LPF Standard Deviation NA Value was not evaluable because only one participant was analyzed.	0.400 cells/LPF Standard Deviation 0.8944	-0.400 cells/LPF Standard Deviation 0.8944	0.000 cells/LPF Standard Deviation 0.0000	0.000 cells/LPF Standard Deviation 0.0000

SECONDARY outcome

Timeframe: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44 and Week 48

Population: The SS consisted of all randomized study participants who received at least 1 dose of IMP.

Urine pH was measured on a pH scale.

Outcome measures

Outcome measures
Measure	Placebo (FAS) n=42 Participants Participants received Placebo during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 16 mg (FAS) n=39 Participants Participants received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg (FAS) n=43 Participants Participants received Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).	BKZ 160 mg LD (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period, forming the Full Analysis Set (FAS).	BKZ 320 mg (FAS) n=41 Participants Participants received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) during the 12 Weeks Double-Blind Period followed by the same dose during the 36 Weeks Dose-Blind Period, forming the Full Analysis Set (FAS).
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 1	-0.138 pH Standard Deviation 0.9198	0.197 pH Standard Deviation 0.5875	0.023 pH Standard Deviation 0.8014	0.085 pH Standard Deviation 0.6011	0.000 pH Standard Deviation 0.8321
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 2	-0.155 pH Standard Deviation 0.9072	0.154 pH Standard Deviation 0.7708	-0.081 pH Standard Deviation 0.7149	0.134 pH Standard Deviation 0.8293	-0.012 pH Standard Deviation 0.7541
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 4	-0.195 pH Standard Deviation 0.9211	0.026 pH Standard Deviation 0.6571	-0.134 pH Standard Deviation 0.8368	0.063 pH Standard Deviation 0.6620	-0.098 pH Standard Deviation 0.6729
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 8	0.000 pH Standard Deviation 0.7826	0.077 pH Standard Deviation 0.7393	-0.024 pH Standard Deviation 0.8762	0.263 pH Standard Deviation 0.7235	0.024 pH Standard Deviation 0.7579
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 12	-0.100 pH Standard Deviation 1.0203	0.237 pH Standard Deviation 0.7600	-0.047 pH Standard Deviation 0.6971	0.211 pH Standard Deviation 0.6641	0.073 pH Standard Deviation 0.8843
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 16	-0.107 pH Standard Deviation 0.8449	0.092 pH Standard Deviation 0.7957	-0.122 pH Standard Deviation 0.8199	0.118 pH Standard Deviation 0.7207	0.088 pH Standard Deviation 0.7240
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 20	-0.113 pH Standard Deviation 0.7884	0.269 pH Standard Deviation 0.8649	-0.012 pH Standard Deviation 0.8300	-0.054 pH Standard Deviation 0.6539	0.063 pH Standard Deviation 0.8929
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 36	-0.211 pH Standard Deviation 0.8353	0.118 pH Standard Deviation 0.7300	-0.195 pH Standard Deviation 0.8506	-0.118 pH Standard Deviation 0.6038	-0.077 pH Standard Deviation 0.7569
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 40	-0.216 pH Standard Deviation 0.9394	-0.041 pH Standard Deviation 0.6388	-0.188 pH Standard Deviation 0.8525	-0.191 pH Standard Deviation 0.5643	-0.154 pH Standard Deviation 0.7448
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 44	-0.458 pH Standard Deviation 0.7780	-0.171 pH Standard Deviation 0.7002	-0.159 pH Standard Deviation 0.9044	-0.167 pH Standard Deviation 0.6693	-0.171 pH Standard Deviation 0.7285
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 48	-0.092 pH Standard Deviation 1.0771	-0.014 pH Standard Deviation 0.7318	-0.200 pH Standard Deviation 0.8533	-0.015 pH Standard Deviation 0.7855	-0.100 pH Standard Deviation 0.7528
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 24	-0.154 pH Standard Deviation 0.9400	-0.013 pH Standard Deviation 0.8011	-0.085 pH Standard Deviation 0.6605	0.100 pH Standard Deviation 0.4820	-0.026 pH Standard Deviation 0.6973
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 28	-0.090 pH Standard Deviation 0.8419	-0.053 pH Standard Deviation 0.6657	-0.122 pH Standard Deviation 0.7313	0.086 pH Standard Deviation 0.6122	-0.088 pH Standard Deviation 0.6783
Changes From Baseline in Urinalysis Parameters During the Study (pH) Week 32	-0.218 pH Standard Deviation 0.8335	-0.079 pH Standard Deviation 0.7491	0.063 pH Standard Deviation 0.8784	-0.103 pH Standard Deviation 0.6717	-0.269 pH Standard Deviation 0.5718

Adverse Events

Placebo (SS) - up to Wk 12

Serious events: 1 serious events

Other events: 8 other events

Deaths: 0 deaths

BKZ 16 mg (SS) - up to Wk 12

Serious events: 0 serious events

Other events: 9 other events

Deaths: 0 deaths

BKZ 160 mg & 160 mg LD (SS) - up to Wk 68

Serious events: 8 serious events

Other events: 40 other events

Deaths: 0 deaths

BKZ 320 mg (SS) - up to Wk 68

Serious events: 0 serious events

Other events: 29 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Placebo (SS) - up to Wk 12 n=42 participants at risk This arm consisted of all participants who received Placebo at any time in the study (up to Week 12). Participants formed the Safety Set (SS).	BKZ 16 mg (SS) - up to Wk 12 n=39 participants at risk This arm consisted of all participants who received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) at any time in the study (up to Week 12). Participants formed the SS.	BKZ 160 mg & 160 mg LD (SS) - up to Wk 68 n=126 participants at risk This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) and Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.	BKZ 320 mg (SS) - up to Wk 68 n=80 participants at risk This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.
Cardiac disorders Atrial fibrillation	2.4% 1/42 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/39 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/126 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/80 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Endocrine disorders Goitre	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/39 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.79% 1/126 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/80 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Hepatobiliary disorders Drug-induced liver injury	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/39 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.79% 1/126 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/80 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Infections and infestations Cellulitis	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/39 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.79% 1/126 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/80 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Infections and infestations Otitis media chronic	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/39 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.79% 1/126 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/80 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Infections and infestations Hepatitis E	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/39 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.79% 1/126 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/80 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/39 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.79% 1/126 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/80 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma in situ	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/39 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.79% 1/126 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/80 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Nervous system disorders Carpal tunnel syndrome	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/39 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.79% 1/126 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/80 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.

Other adverse events

Other adverse events
Measure	Placebo (SS) - up to Wk 12 n=42 participants at risk This arm consisted of all participants who received Placebo at any time in the study (up to Week 12). Participants formed the Safety Set (SS).	BKZ 16 mg (SS) - up to Wk 12 n=39 participants at risk This arm consisted of all participants who received Bimekizumab (BKZ) 16 milligrams (mg) every 4 weeks (Q4W) at any time in the study (up to Week 12). Participants formed the SS.	BKZ 160 mg & 160 mg LD (SS) - up to Wk 68 n=126 participants at risk This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg at Baseline followed by 160 mg every 4 weeks (Q4W) and Bimekizumab (BKZ) 160 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.	BKZ 320 mg (SS) - up to Wk 68 n=80 participants at risk This arm consisted of all participants who received Bimekizumab (BKZ) 320 mg every 4 weeks (Q4W) at any time in the study (up to Week 68). Participants formed the SS.
Infections and infestations Ear infection	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	5.1% 2/39 • Number of events 2 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.79% 1/126 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/80 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Infections and infestations Respiratory tract infection	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	5.1% 2/39 • Number of events 2 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	6.3% 8/126 • Number of events 8 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	2.5% 2/80 • Number of events 3 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Infections and infestations Bronchitis	2.4% 1/42 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/39 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	5.6% 7/126 • Number of events 8 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	3.8% 3/80 • Number of events 3 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Infections and infestations Nasopharyngitis	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	7.7% 3/39 • Number of events 3 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	9.5% 12/126 • Number of events 15 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	13.8% 11/80 • Number of events 11 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Infections and infestations Pharyngitis	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/39 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	3.2% 4/126 • Number of events 4 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	8.8% 7/80 • Number of events 7 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Infections and infestations Upper respiratory tract infection	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	2.6% 1/39 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	9.5% 12/126 • Number of events 12 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	10.0% 8/80 • Number of events 10 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Musculoskeletal and connective tissue disorders Psoriatic arthropathy	7.1% 3/42 • Number of events 4 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	5.1% 2/39 • Number of events 2 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	1.6% 2/126 • Number of events 2 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	1.2% 1/80 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Psychiatric disorders Insomnia	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	5.1% 2/39 • Number of events 2 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/126 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	3.8% 3/80 • Number of events 4 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/42 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	5.1% 2/39 • Number of events 2 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/126 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	1.2% 1/80 • Number of events 1 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.
Vascular disorders Hypertension	9.5% 4/42 • Number of events 4 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/39 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	0.00% 0/126 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.	2.5% 2/80 • Number of events 2 • Adverse events (AEs) were collected from Baseline until the Safety Follow-Up Visit (up to Week 68) At Week 12, Placebo and BKZ 16 mg subjects were re-randomized to either BKZ 160 mg or BKZ 320 mg. Subjects randomized to BKZ 160 mg or BKZ 320 mg at Baseline were not re-randomized at Week 12 and remained on their treatment. The Safety Set is based on actual treatment, other populations are based on planned treatment. 160mg LD is considered 160mg.

Additional Information

UCB

Cares

Phone: +1844 599

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: GT60